Vimentin Overexpression Contributes To the Biological Properties of Metastatic Head and Neck Cancer Cells by Paccione, Rachel J.
Virginia Commonwealth University
VCU Scholars Compass
Theses and Dissertations Graduate School
2005
Vimentin Overexpression Contributes To the
Biological Properties of Metastatic Head and Neck
Cancer Cells
Rachel J. Paccione
Virginia Commonwealth University
Follow this and additional works at: http://scholarscompass.vcu.edu/etd
Part of the Biochemistry, Biophysics, and Structural Biology Commons
© The Author
This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses
and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/etd/1084
O Rachel Josephine Paccione 2005 
All Rights Reserved 
Vimentin Overexpression Contributes to the Biological Properties of 
Metastatic Head and Neck Cancer Cells 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science at Virginia Commonwealth University School of Medicine. 
Rachel Josephine Paccione 
Bachelor of Arts, University of Virginia, May 2003 
Master of Science, Virginia Commonwealth University, December 2005 
Director: W. Andrew Yeudall 
Interim Director Philips Institute of Oral and Craniofacial Molecular Biology 
Department of Biochemistry 
Virginia Commonwealth University School of Medicine 
Richmond, Virginia 
December, 2005 
Vimentin Overexpression Contributes to the Biological 
Properties of Metastatic Head and Neck Cancer Cells 
Rachel J. ~accione'< Hiroshi ~ i ~ a z a k i ' ,  
1,2294 Zendra E. zehner2' and W. Andrew Yeudall . 
Philips Institute1, Department of ~iochemis#, and Massey Cancer center3, Virginia 
Commonwealth University, Richmond, VA 23298, USA. 
corresponding author: Philips Institute of Oral and Craniofacial Molecular Biology, 
P.O. Box 980566, Richmond, VA 23298-0566, USA. 
Phone: (804) 828-64 15 
Fax: (804) 828-0 150 
E-Mail: waveudall @vcu.edu 
Keywords: EMT, growth factor, metastasis, oral cancer, gene regulation 
Acknowledgements 
I would like to take this opportunity to thank my parents, Michael and Maryanne 
Paccione, for all of your love, support, and guidance. Thank you for not only being a 
friend these last couple of years, but also providing words of wisdom, insight, and advice 
as parents. To my brother, Michael, for always reminding me to not sweat the small stuff 
and roll with the punches. You have taught me that life is too short and to just give it 
your best shot. To Nonna, for I do not know where I would be today without your daily 
words of encouragement and prayers. To my twin sister, Kristin, for we seem to get 
through everything some way or another together. I would not have made it without you! 
To my advisor Dr. Andrew Yeudall, for your endless support, guidance, and 
encouragement. Thank you for believing in me and providing me with essential life 
lessons learned through this laboratory experience. To Dr. Hiro Miyazaki, for your 
expectations of me, your fatherly advice, and teaching me everything I know when it 
comes to bench research. Thank you both for sparking my passion for research, 
supporting me to never give up, and serving as incredible role models that I hope one day 
to exemplify. To my dog, Bailey girl, for your company during long nights and runs as 
study breaks. And last and but not least, to my best friend, Ray Dunn. Your strength, 
support, guidance, and positive attitude have been instrumental in my academic pursuits. 
You have taught me that life is a journey not a race. I dedicate this thesis to each one of 
you because your support and guidance is what made it possible. Thank you. 
Table of Contents 
... 
................................................................................... Acknowledgement 111 
......................................................................................... List of Tables iv 
.......................................................................................... List of Figures v 
................................................................................................ Abstract vi 
........................................................................................... Introduction 1 
............................................... Growth Control and Tumor Development 1 
Metastasis ........ : ........................................................................... 5 
.................................................................... Head and Neck Cancer -7 
...................................................... Intermediate Filaments and Cancer -9 
................................................................................... Vimentin -10 
.................................. Vimentin and Epithelial to Mesenchymal Transition 1 1  
............................... Cytokeratin and Epithelial to Mesenchymal Transition 12 
Vimentin Gene Expression ................................................................ 13 
............................................................................. Growth Factors 14 
...................................................... Transforming Growth Factor-Beta 15 
.................................... Introduction to Transforming Growth Factor-Beta 15 
..................................... TGF-P - Tumor Suppressor or Tumor Promoter? 16 
..................................... TGF-P Signaling Pathway in Tumor Progression 18 
.............................................................. TGF-P and Smad Signaling 18 
.............................. TGF-P signaling through Smad Independent Pathways 22 
........................................................................... TGF-P and EMT 22 
......................................................... TGF-P Stimulates Angiogenesis 23 
................................................................ Epidermal Growth Factor 24 
................................................ Epidermal Growth Factor Introduction 24 
.............................. Epidermal Growth Factor and Head and Neck Cancer 26 
............................... Matrix Metalloproteinases in Head and Neck Cancer 27 
................... Phospholipase C gamma (PLCy-1) and Head and Neck Cancer 29 
................................ .................... EGFR and Focal Adhesion Kinase : 30 
................................................................. EGFR and Angiogenesis 32 
............................................................... Aims of the Current Study 33 
................................................................................. Paper Introduction 34 
........................................................................... Materials and Methods -38 
.............................................................................. Cell Cultures -38 
.................................................................................... Plasrnids 38 
.................... Generation of Cell Lines that Stably Express shRNA Plasmids 39 
...................................................... Cell Transfection and CAT Assay 40 
................................................................... Western Blot Analysis 40 
..................................................................... Immunofluorescence 41 
................................................................... Immunoc ytochemistry 42 
.......................................................................... Migration Assay 42 
Invasion Assay ............................................................................. 43 
Proliferation Assay ....................................................................... -44 
.................................................................................... qRT-PCR 44 
Results ............................................................................................... -46 
............................................... Upregulation of Vimentin in HN12 cells 46 
EGF and TGF-P Synergize to Increase Vimentin Expression ....................... 50 
Targeted Suppression of Vimentin Expression ........................................ 54 
Vimentin Overexpression is Important for Biological Properties of HN12 Cells.59 
Regulation of Vimentin Promoter Activity in HN12 Cells by EGF and TGF-P ... 63 
Discussion ............................................................................................ 71 
Aims of Current Study ..................................................................... 71 
HNSCC Model System .................................................................... 71 
Microarray Data ........................................................................... -72 
Vimentin as a Molecular Marker ......................................................... 72 
................................................ Upregulation of Vimentin in HN12 cells 73 
Vimentin Expression and Epithelial to Mesenchymal Transition ................... 74 
. Vimentin Expression Suppressed in HN 12 Cells ...................................... 76 
Vimentin Expression and Biological Properties ....................................... 76 
Vimentin Expression is Important for the Biological Properties of HNSCC ....... 76 
Vimentin Expression and Biological Properties of Other Cell Lineages ........... 77 
Expression of the Vimentin Promoter in HN12 Cells ................................. 78 
EGF and TGF-P and Vimentin Expression ............................................. 83 
......................................... EGF and TGF-P and the Vimentin Promoter 84 
.............................................................. TGF-P and Tumorigenesis .85 
......................................................... TGF-P and APl Binding Sites 86 
............... TGF-P Induction via Smad Dependent and Independent Pathways 87 
........................................................................ EGFR Induction -89 
......................................................... EGF and sp 1 Binding Protein -89 
............................................................ Stat3 Protein and Metastasis 90 
............................................................................... Conclusion -92 
............................................................................... Future Experiments 94 
....................................... Downregulation of Cytokeratin in HN12 cells 94 
List of Tables 
Table Page 
1. Combinatorial Interactions of Type I1 and Type I Receptors Define the Signaling 
Responses. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .20 
List of Figures 
Figure Page 
.................................................. 1 . Sequential Steps of the Metastatic Cascade 7 
................................................ 2 . GFP-Vimentin in a Living Endothelial Cell 11 
............................................................ 3 . In Vitro EMT in Carcinoma Cells 13 
4 . Diagram of the Relative Position of Vimentin's Previously Reported Regulatory 
..................................................................................... Elements 14 
........................................................... 5 . Model of TGF-P Action in Cancer 16 
.......................... 6 . General Mechanism of TGF-P Receptor and Smad Activation 19 
7 . R-Smad Activation Regulated by Receptor Interacting Proteins and Smad 617 ....... 21 
..................................................................... 8 . EGFR Signaling Pathway 25 
........ 9 . Signal Transduction Elements Important to HNSCC Invasion and Metastasis 27 
10 . MMP Cascade of Zymogen Activation Involved in pro-MMP-9 Activation .......... 29 
1 1 . Focal-Adhesion Kinase as a Signal Integrator .............................................. 31 
12 . Focal-Adhesion Kinase Influences Cell Migration through Additional Molecular 
........................................................................ Signaling Pathways 32 
................................................... 13 . Upregulation of Vimentin in HN 12 Cells 47 
........................... 14 . EGF and TGF-P Synergize to Increase Vimentin Expression 52 
............................................. 15 . Targeted Suppression of Vimentin Expression 56 
16 . Vimentin Overexpression is Important for the Biological Properties of HN12 Cells.60 
17. Regulation of Vimentin Promoter Activity in HN 12 Cells by EGF and TGF-P.. . . . .65 
18. Downregulation of Cytokeratin in HN12 Cells.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .94 
Abstract 
VIMENTIN OVEREXPRESSION CONTRIBUTES TO THE BIOLOGICAL 
PROPERTIES OF METASTATIC HEAD AND NECK CANCER CELLS 
Rachel Josephine Paccione 
Master of Science 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science at Virginia Commonwealth University School of Medicine. 
Virginia Commonwealth University, 2005 
Major Director: W. Andrew Yeudall, Interim Director 
Philips Institute of Oral and Craniofacial Molecular Biology, Biochemistry 
Epithelial to mesenchymal transition occurs in the later stages of epithelial tumor 
progression, with cells expressing mesenchymal markers. Of these, the intermediate 
filament protein vimentin is frequently upregulated in metastatic carcinomas. Previously, 
microarray studies showed that the gene encoding vimentin is highly upregulated in 
metastatic HN12 cells compared to a related primary tumor cell line. In this study, we 
confirmed this difference using real-time quantitative PCR, western blot analysis, and 
irnmunostaining. Furthermore, EGF and TGF-P, growth factors that induce migration 
and invasion of HN12 cells, produced synergistic increases in vimentin expression. To 
assess the contribution of vimentin to the biological properties, HN12 cells were stably 
transfected with a plasmid that directs synthesis of vimentin shRNA. Clones expressing 
decreased amounts of vimentin were isolated and characterized. These cells showed 
significantly reduced proliferation compared to non-targeting controls. Moreover, 
downregulation of vimentin led to a decrease in cell motility, as well as reducing their 
ability to invade through a basement membrane substitute. Using transient transfection 
assays, vimentin promoter activity was determined in HN12 cells to define regulatory 
elements important for controlling vimentin upregulation in the absence or presence of 
EGF and TGF-P. Taken together, the data indicate that overexpression of vimentin is 
important for proliferation and invasion of metastatic HN12 cells, and suggest that EGF- 
dependent pathways target binding elements in the proximal vimentin promoter, while 
TGF-P is likely to act in an API-dependent manner. Furthermore, both growth factors 
appear to synergize by stimulating promoter activation through the ASE site, suggesting 
involvement of Stat-dependent pathways in regulation of vimentin expression in HN12 
cells. 
1. Introduction 
1.1. Growth Control and Tumor Development 
Cancer is caused by the failure of regulatory mechanisms that control the growth 
and survival of cells. During normal development, intricate genetic control systems 
regulate the balance between cell proliferation and cell death in response to growth 
promoting signals, growth-inhibitory signals, and death signals. The growth of tumor 
cells depends not only on the increase of cells that are proceeding through cell division, 
but also a decrease in the number of cells that are undergoing programmed cell death 
(Martin, 1996). Programmed cell death or apoptosis is a physiological process that 
embodies a series of characteristics and genetically controlled steps, which include 
chromatin condensation and fragmentation, cell shrinkage, and the engulfment of the cell 
by neighboring cells without an inflammatory response (Martin, 1996). Apoptosis is 
essential for both normal development and tissue homeostasis in the adult (Stellar, 1995). 
It is the failure of certain tumor cells to undergo apoptosis that appears to be one of the 
factors underlying the genetic instability of these particular cells, their resistance to 
chemotheurapeutic agents, and their increase in proliferation (Martin, 1996). 
The loss of cellular regulation contributes to the genesis of malignancies and is 
due in large part to genetic damage. Genetic changes in proto-oncogenes and tumor 
suppressor genes are primarily responsible for the initiation and progression of a tumor 
(Martin, 1996). Since the majority of mutations do not increase the growth 
characteristics of a cell, specific genetic changes must underlie the progression to cancer 
(Lowy, 1996). For instance, proto-oncogenes may be activated to become oncogenes by 
a particular mutation, which causes the gene to become excessively active in growth 
promotion, or they may bc expressed inappropriately. In addition, tumor suppressor 
genes that normally restrain the growth of cells can be inactivated, thereby de-regulating 
cell growth. 
Proto-oncogenes are appropriately named because they are essentially progenitors 
of oncogenes or precursors of cancer genes. Proto-oncogenes can be converted into 
oncogenes by several mechanisms, including intragenic mutation and chromosomal 
rearrangement (Bishop and Hanafusa, 1996). In either case, the result is the abnormal 
uninhibited expression of a gene or the deregulation of the protein product (Bishop and 
Hanafusa, 1996). Proto-oncogene products participate in cell signaling that drives cell 
growth and usually falls into one of four categories: growth factors, growth factor 
receptors, intracellular signal transducers, and transcription factors (Leis and Livingston, 
1996). Oncogenes may be associated with a cancer predisposition as a result of a 
mutational event in many types of cancers, they may gain function through a dominant 
allele in which only one allele is mutated in cancer, and are rarely passed on to progeny 
through germ line transmission (Leis and Livingston, 1996). On the other hand, tumor 
suppressor genes are negative regulators of cell growth that undergo loss of function 
through mutation of both alleles, although for some genes, loss of a single allele is 
enough to perturb suppressor function (haploinsufficiency). Germ line transmission of a 
mutant allele results in predisposition to developing malignant disease (Leis and 
Livingston, 1996). 
As noted previously, oncogenic mutations usually only occur in somatic cells; 
therefore, the mutations are not passed from one generation to another. In order for 
oncogenic mutations to induce cancer, the mutations must occur in the dividing cells and 
therefore be passed to progeny cells. When such a mutation occurs in nondividing cells, 
e.g. neurons or muscle cells, the mutation generally does not induce cancer, which is one 
reason why tumors of muscle and nerve cells are very rare in adults. 
However, there are certain inherited mutations in tumor suppressor genes, for 
example mutations in RB and BRCAI, which are carried through the germ-line and 
increase the probability that cancer will occur during an individual's lifetime (Leis and 
Livingston, 1996). Mutations in the proto-typical tumor suppressor genes generally 
behave in a recessive manner at the molecular level and therefore it is only when both 
copies of the gene become inactivated that an abnormal phenotype will manifest in the 
cell (Leis and Livingston, 1996). It is due to this recessive genetic behavior that a single 
mutant allele of such a gene can be passed through the germ line which is tolerated 
during embryogenesis because its presence is revealed in a tissue only when the 
remaining wild-type allele is lost (Leis and Livingston, 1996). 
Oncogenic mutation or loss of tumor suppressor function may result in cancer 
cells acquiring a proliferative potential that does not necessarily require an external 
inducing signal. In addition, these cells may fail to sense particular signals that restrict 
cell division and continue to grow within the tissue when they should otherwise 
differentiate or die. Furthermore, cancer cells often alter their attachment to adjacent 
cells and to extracellular matrix in order to gain the potential to migrate and invade into 
surrounding tissues. 
Tumor cells must develop a blood supply in order to survive in the tissue, a 
process known 2s angiogenesis. Angiogenesis is a complex phenomerion ,of 
neovascularization that facilitates provision of nutrients to sustain the continued growth 
and survival of tumor cells. Without this, tumor growth would be severely limited. 
Angiogenesis requires several discrete steps; degradation of the basal lamina surrounding 
a nearby capillary, migration of endothelial cells lining the capillary into the tumor, 
endothelial cell division, and the formation of a new basement membrane around the 
newly elongated capillary. During the early stages of cancer, an abundant amount of new 
capillaries usually exists along the basement membrane below the transformed epithelium 
(Weinberg and Hanahan, 1996). However, if neovascularization persists in an invasive 
cancer, then the capillaries have the ability to breach the basement membrane and invade 
through the stroma (Weinberg and Hanahan, 1996). Interestingly, it is thought that 
transforming growth factor P (TGF-P) may play an important role in angiogenesis 
because along with other angiogenic factors, cells release TGF-P during development and 
tissue repair as part of a mechanism that promotes the vascularization of normal tissues 
(Weinberg and Hanahan, 1996). 
The majority of benign tumors pose little risk to the host because they remain 
localized and are small. The cells that compose a benign tumor resemble and may even 
function like normal cells while maintaining cell adhesion and thereby restricting the 
tumor to the site of origin. In contrast, malignant tumor cells have the capability of 
dividing rapidly compared to normal cells, as well as enhanced survival. Thus, malignant 
cells usually exhibit the characteristics of rapidly growing cells, that is, high nucleus-to- 
cytoplasm ratio, prominent nucleoli, and relatively little specialized structure. The major 
characteristics that differentiate malignant tumors from benign lesions are their 
invasiveness and ability to spread to local, regional and distant body sites. 
1.2. Metastasis 
Metastasis occurs when a tumor invades into the surrounding tissue, gets into the 
circulatory or lymphatic systems, allowing the cells to spread to regional or distant sites 
and facilitating the establishment of secondary foci of proliferation. Invasion of the 
underlying connective tissue proceeds in stages and is mediated by various factors 
produced by the tumor cell (Weinberg and Hanahan, 1996). For metastasis to occur, 
tumor cells must release proteases such as collagenase IV, which dissolves the collagen 
in the basement membrane allowing the tumor to penetrate the subjacent stroma. These 
invasive cancers express membrane-localized receptors for laminin and fibronectin, 
which are large glycoprotein components of the basement membrane and connective 
tissue stroma, respectively. It is the binding of these elements that provides the tumor 
cells with a lattice for anchorage and attachment. Enzymes such as plasminogen 
activators, collagenases I, cathepsins, heparanase, and hyaluronidase are released by the 
tumor cells and destroy the matrix constituents, thereby enabling the cells to advance 
further into the connective tissue (Weinberg and Hanahan, 1996). 
However, fewer than 1 in 10,000 cells that escape from the primary tumor site 
survive to colonize another tissue and form a secondary, metastatic tumor. In the case of 
hematogenous spread, cells that escape the primary tumor must adhere to the endothelial 
lining of a capillary and migrate across or through it to the underlying tissue in order to 
enter circulation. In addition, tumor cells secrete autocrine motility factors.that direct 
their migration, as well as vascular permeability factors that allow plasma proteins to 
accumulate in the tumor and angiogenic factors that increase the vascularity of the tumor 
(Weinberg and Hanahan, 1996). 
As the tumor develops, the cells become very well adapted to growth and invasion 
of the surrounding tissues. The invasion of tissues is nonrandom, depending on the nature 
of both the metastasizing cell and the invaded tissue. It is thought that the tumor cells 
preferentially invade along the pathways that provide the least resistance, such as the 
connective tissue stroma (Weinberg and Hanahan, 1996). 
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Figure 1: Sequential steps of the metastatic cascade. The process of metastasis 
begins when an individual tumor cells detaches from the primary tumor. The 
progression to metstasis requires individual tumor cells adhering and invading 
through the basement membrane, migrating through extracellular matrix, and 
intravasating into blood or lymphatic vessels, where the tumor cells can 
disseminate to distant sites. In addition, the tumor cells must extravasate out of 
the vessel and invade into the target organ, which forms a metastatic tumor. 
(Howell and Grandis, 2005) 
1.3. Head and Neck Cancer 
Squamous cell carcinoma of the head and neck region (HNSCC) is the sixth most 
common malignancy worldwide, representing 6% of all cancers. Each year 
approximately 40,000 individuals in the United States are diagnosed with HNSCC (Kim 
and Califano, 2004) and more than two-thirds of these cases will present with advanced 
stages (stage I11 and IV) (AJCC, 1983). The 5-year survival rate has remained largely 
unchanged over the last two decades at 50% despite the significant improvements in the 
treatment of this disease that has decreased morbidity (Kim and Califano, 2004). Studies 
have shown that if the patient survives the initial lesion, a constant and continuing risk 
(from 2.7-4% per year) of secondary primary tumor formation exists following the initial 
treatment (Jovanovich et al., 1994). The probability of a second malignancy forming 
within five years after the presentation of the initial tumor may be as high as 22% 
(Dhooge et al., 1998). 
Head and neck squarnous cell carcinoma (HNSCC) is a locally aggressive 
malignancy that may develop after years of prolonged abuse of alcohol and tobacco 
products. Exposure to these particular agents results in alterations in genes that are 
important for the regulation of various cellular functions, which allows tumor cells to 
survive and grow in an uninhibited manner, as discussed above (section 1.1). Some of 
these important functions include the acquisition of immortality, the ability to invade 
tissue andlor metastasize to other sites, and acquiring the ability to induce angiogenesis 
(Hasina and Lingen, 2001). 
HNSCC generally responds inadequately to chemotherapeutic and 
radiotherapeutic measures; therefore, surgery remains the primary treatment. However, 
patients with locally advanced, operable (HNSCC) are known to be at high risk of 
treatment failure, which ranges from local regrowth to lymphatic spread and systemic 
dissemination (Bernier and Cooper, 2005). HNSCC lesions are locally aggressive and 
frequently metastasize to local and regional lymph nodes. Therefore, treatment of 
HNSCC must address not only the initial primary lesion, but also early diagnosis of high- 
risk pre-malignant lesions to prevent malignant development and progression. Poor long- 
term survival is due to numerous variables including delayed diagnosis as well as the 
development of multiple primary and secondary tumors. Thus, in addition to early 
detection, continued emphasis must be placed on preventing the development of 
secondary tumors as well a? establishing more effective treatments for individuals who 
present with advanced disease. 
1.4. Intermediate Filaments and Cancer 
The intermediate filament protein family consists of at least 65 distinct proteins, 
in which all assemble into 10 nm wide filaments and serve as prominent structural 
elements both in the nucleus and the cytoplasm (Herrmann and Aebi, 2004). The family 
comprises both nuclear (lamins) and cytoskeletal proteins such as cytokeratins, vimentin, 
desmin, glial fibrillary acidic protein, neurofilaments, internexin, nestin, and peripherin 
(Steinert and Leim, 1990). Two other principal structural elements of the eukaryotic cell 
cytoskeleton are microtubules and microfilaments. Compared to both microtubules and 
rnicrofilarnents, which often break when subjected to shear stress, intermediate filaments 
become viscoelastic and are flexible (Janmey et al, 1998). The molecular building blocks 
of intermediate filaments are fibrous proteins that consist of long, uninterrupted segments 
of a-helices. Since single a-helical chains are unstable in aqueous solution, they often 
adopt a rope-like structure by forming multistranded left-handed coiled coils (Watson and 
Crick, 1953). With the use of electron microscopy, it has been shown that coiled-coil 
intermediate filaments protein dimers are 45 to 50 nm long rod-like molecules. 
Intermediate filament proteins may be useful for the diagnosis of certain tumors 
because of their distinct expression patterns. For example, in some malignant tumors the 
cells lose their normal appearance and, therefore, their origin is unable to be identified 
purely on morphological grounds. However, the expression of particular intermediate 
filament proteins is one of the differentiated properties of the cell that may be retained in 
tumor cells. Hence, with the use of antibodies specific for the intermediate filament 
protein of interest, researchers can determine exactly where the tumor originated, 
epithelial, mesenchymal, or neuronal tissue. Identifying the intermediate filament protein 
in a tumor cells may allow physicians to select the most effective treatment because 
epithelial and mesenchymal malignancies may be sensitive to different therapeutic 
regimes. 
1.4.1. Vimentin 
The fact that intermediate filaments span from the nucleus to the cell membrane 
suggests that intermediate filaments have the potential to play significant roles in the 
structural stability of the cell and the ability to transmit andlor transduce mechanical 
signals into biological responses (Coulombe et al., 2000). Vimentin, which is a major 
structural component of intermediate filaments in many different cell types, has been 
shown to play a significant role in essential mechanical and biological functions 
including cell contractility, migration, and proliferation (Wang and Starnenovic, 2002). 
Live imaging of cells expressing the GFP-vimentin fusion protein revealed that 
the vimentin network is motile, with the filaments constantly changing the shape of the 
cell (Yoon et al., 1998; Helfand et al., 2002). It is the motile properties of vimentin 
filaments that are particularly evident in the spreading cell, in which three different 
structural forms of vimentin are involved in the assembly of the vimentin network 
(Prahlad et al., 1998). 
Figure 2: GFP-vimentin in a living endothelial cell. (Helmke et al., 2000) 
1.4.2. Vimentin and Epithelial to Mesenchymal Transition 
Vimentin serves as an appropriate marker for EMT because it is an established 
marker for the mesenchymal cell and is not normally expressed in cells of epithelial 
origin. EMT is one feature that may characterize the progression of a tumor toward a 
highly malignant phenotype, and involves numerous changes in gene expression that 
result in the substitution of epithelial characteristics for those of the mesenchymal cell 
(Gilles and Thompson, 1996). Typically, cells that have undergone EMT exhibit a 
spindle-shaped morphology with organized cytoskeleton, reduced cellular adhesions, and 
the expression of specific mesenchymal cell markers such as vimentin. This correlation 
between EMT and increased vimentin expression has been shown in a variety of tumor 
cells, including invasive breast cancer cells (Korsching et al., 2005) and liver metastasis 
of a pancreatic carcinoma (Nakajima et al., 2004). In addition, it has been shown that 
many growth factors and cytokines induce EMT (Boyer et al., 2000; Thiery, 2002). 
1.4.3. Cytokeratin and Epithelial to Mesenchvmal Transition 
Whereas vimentin is turned on during EMT, a normal epithelial specific 
intermediate filament, cytokeratin, is downregulated andlor switched to a different 
isoform (Wu et al., 2003). In vivo studies and experimental models show that epithelial 
cells are polarized, display cytokeratin filaments and membrane-associated specialized 
junctions such as demosomes and adherens junctions (Hay, 1995; Savagner et al., 1994). 
It is after EMT when these epithelial features are lost and the acquisition of mesenchymal 
characteristics occurs, which includes vimentin filaments and a flattened phenotype (Hay, 
1995; Savagner et al., 1994). Therefore, cytokeratins are highly regulated during EMT 
and progressively vanish from within the cell when the vimentin level inside the cells 
increases and adopts a mesenchymal phenotype (Boyer et al., 1989). 
It has been proposed that EMT represents a permanent switch from cytokeratin to 
vimentin in certain tumors (Gilles et al., 1997), consistent with the findings of an 
androgen-independent model of prostate cancer which demonstrated an increase in 
vimentin expression of the metastatic cell line accompanied by a decrease in the levels of 
cytokeratin (Singh et al., 2003) as well as mammary epithelial cells that underwent EMT 
in response to transfection with the matrix metalloproteinase stromelysin 1 (Lochter et 
al., 1997). 
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Figure 3: In vitro EMT in carcinoma cells. After EMT, the cells express 
mesenchymal cell markers such as vimentin, become individualized, spread, and 
migrate. (Savagner, 200 1) 
1.4.4 Vimentin Gene Expression 
Vimentin expression is upregulated in some metastatic tumor cells, making it a 
potential marker of oncogenic progression. The promoter of the vimentin gene contains 
multiple elements responsible for its complex transcriptional regulation, including a 
TATA-box, several positive regulatory elements that include eight GC-boxes (Rittling 
and Baserga, 1987), a PEA3 site (Chen et al., 1996), an NF-KB site (Lilienbaum and 
Paulin, 1993), A19 site (Salvetti et al., 1993), a PS element (Wieczorek et al., 2000), two 
tandem AP-1 binding sites (Rittling et al., 1989), a 0-catenin site (Gilles et al., 2003), an 
antisilencer (ASE) element (Izmailova and Zehner, 1999), and a proximal silencer 
element (Salvetti et al., 1993). Determining what controls vimentin expression could 
lead to an understanding of what contributes to the changes in gene expression that 
occurs during transformation to the malignant state. 
-800 -600 
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Figure 4: A diagram of the relative position of vimentin's previously reported 
regulatory elements; Gc-box 1, PEA3, NF-KB, PS, H4TF-1, tandem AP- 1 binding 
sites, and ASE. 
1.5. Growth Factors 
Growth factors interact with specific protein receptors at the cell surface, which 
are generally proteins that traverse the lipid bilayer of the plasma membrane. The growth 
factor receptors contain an external ligand-binding domain and a cytoplasmic domain, 
which triggers further biochemical events within the cell. The term "signal transduction" 
is used to characterize this process in which binding of the growth factor leads to the 
activation of specific intracellular pathways. The activated receptor induces a change at 
the cytoplasmic side of the membrane by either becoming enzymatically active or by 
interacting with other regulator proteins at the plasma membrane. This leads to a series 
of events in the cytoplasm; for example, changes in ion concentration, production of 
second-messengers, or activation of protein kinases, which are the enzymes that 
phosphorylate other protein substrates. These cytoplasmic signals can then alter gene 
expression within the nucleus. (Bishop and Weinberg, 1996) 
In normal tissue, adjacent cells or distant cells that have the ability to produce and 
release growth factors control the amount of growth factor available to the cell, which 
ensures normal levels of proliferation. However, certain cells have the ability to undergo 
autocrine stimulation in which they have the capability of expressing both the growth 
factor and the receptor. Therefore, once the growth factor is secreted it can be considered 
to be constantly in the active state because subsequent binding of the growth factor to the 
receptor stimulates a cellular response. Therefore, normal regulatory events that prevent 
prolonged interaction of the growth factor and its receptor are bypassed, thereby 
contributing to cellular transformation. (Pawson, 1996) 
1.6. Transforming Growth Factor-Beta 
1.6.1. Introduction to Transforming Growth Factor-Beta 
The mammalian transforming growth factor-beta (TGF-P) family consists of five 
isoforms: TGF-PI, TGFP-2, TGFP-3, TGFP-4 and TGFP-5. All are secreted and 
activated in the extracellular environment and bind to receptors at the cell surface 
receptors, of which there are three types: TGF-PI, TGF-PII, and TGF-PIII. The TGF-P 
isoforms share 64-82% similarity at the amino acid level, largely due to a conserved 
cysteine knot structure that is characteristic of the TGF-P monomer (Archer et al., 1993; 
Daopin et al., 1992; Schlunegger and Grutter, 1992). Interestingly, the type I11 receptor 
is also known as a betaglycan and can exist in a soluble form that has the ability to bind 
two TGF-P molecules (Bachman and Park, 2005). Therefore, it is this increased binding 
capacity which allows a greater concentration of TGF-P molecules to be present at the 
cell surface, thus maximizing the interaction of TGF-P with type I and type I1 receptors 
(Lopez-Castillas, et al., 1993) which transduce the signal to the intracellular environment. 
Recent advances in molecular biology reveal that tumor development requires the 
accumulation of a particular set of cellular characteristics. These include the ability to 
grow independently of exogenous growth factors, to divide indefinitely, to grow new 
blood vessels, and to invade surrounding tissues. The TGF-P signaling pathway regulates 
many of these cellular processes, and tumor cells may exploit alterations in TGF-P 
signaling cascade to promote malignant progression (Rich et al., 2001). 
1.6.2. TGF-8 - Tumor Suppressor or Tumor Promoter? 
Normal Benign Malignant Metastatic 
TGF-p overexpression 
Figure 5: Model of TGF-P action in cancer. 
TGF-P is a cytokine that is known for its ability to inhibit epithelial proliferation. 
However, many epithelial malignancies acquire a resistance to the growth-inhibitory 
effects of TGF-P. Therefore, it is thought that this resistance is part of a particular 
signaling event is which TGF-P loses its growth inhibitory effects and is then used by the 
epithelial cells to promote cell growth (Bachman and Park, 2005). 
It is important to note that in some model systems, mutated TGF-P receptors 
appear to block TGF-P signaling completely because neither growth-inhibitory nor 
growth-promoting responses are observed (Bachman and Park, 2005). Therefore, it is 
thought that the decision of the cancer cell to use TGF-P as a tumor suppressor instead of 
as a tumor promoter is not mediated at the level of the ligandlreceptor interaction. 
Over the last decade, numerous studies have demonstrated that TGF-P1 not only 
maintains transforming potential but can also drive malignant progression, invasion and 
metastasis both in vitro and in vivo (Derynck et aL., 2001). It has now become clear that 
TGF-P can act as both a tumor suppressor in which three isoforms bind to the same type 
I1 receptor (Akhurst and Derynck, 2001) and as a significant stimulator of tumor 
progression, invasion, and metastasis (Cui et al., 1996). 
At the early stages of tumorigenesis when the lesion is still benign, TGF-P acts 
directly on the cancer cells to suppress tumor growth. However, as the tumor progresses, 
genetic and/or biochemical changes allow the TGF-P to stimulate tumor progression on 
both the cancer cell and on the non-malignant stromal cell types on the tumor (Akhurst 
and Derynck, 2001). It is this stimulation and metastasis caused by TGF-P that might be 
of greater clinical significance because a majority of tumors retain the functional TGF-P 
signaling pathway. 
1.6.3. TGF-B Signaling Pathway in Tumor Progression 
Two general mechanisms may explain the contribution of TGF-P signaling to 
enhance tumor progression, invasion, and metastasis. First, there can be an early loss of 
signaling components, such as the type I1 TGF-P receptor, leading to rapid tumor cell 
growth. It is this increased cell division that also potentiates the probability of further 
cancer-causing mutations and cytogenetic changes that have the ability to drive tumor 
progression. Second, the TGF-P signaling pathway can remain intact, but become 
disrupted by other mechanisms such as deregulated Smad signaling. The altered Smad 
signaling leads to a direct increase in tumor cell plasticity, invasion, and metastasis. 
(Akhurst and Derynck, 2001) 
1.6.4. TGF-I3 and Smad Signaling 
Ligand 
. / 4 TGF-P Signaling Pathway 
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Figure 6: General mechanism of TGF-/3 receptor and Smad activation. 
TGF-P is secreted from cells as a biologically inactive latent form that requires 
some processing to generate the active growth factor. At the cell surface, TGF-P binds to 
a complex of transmembrane receptor serineltheorine kinases (type I and 11) and induces 
the phosphorylation of the GS segment on the type I receptor by the type I1 kinases. This 
heterodimeric transmembrane receptor complex is composed of type I1 (TPRII) and type 
I receptors (AlkSlTPRI) (Glick, 2004). The type I1 receptor is a constitutive kinase and 
capable of binding TGF-P1 on its own (Glick, 2004). However, the type I receptor 
kinase is only activated after complex formation and trans-phosphorylation by the type I1 
receptor (Glick, 2004). 
Ligand Type11 Type I R-Smad 
TGF-P TPRII ALK5 (TPRII) Smad2 
ALK- 1 Smad3 
ALK-2 Smadl 
Smad5 
Table 1: Combinatorial interactions of type I1 and type I receptors define the 
signaling responses. 
The activated type I receptor phosphorylates selected Smad proteins at serine 
residues within the C-terminal region. These receptor-activated Smads (R-Smads) then 
form a complex with Smad4 (Derynck and Zhang, 2003). Smad2 and Smad3 are the 
major substrates for the activated type I kinase (Glick, 2004). These proteins are inactive 
cytoplasmic transcription factors until they become phosphorylated by the ligand-bound 
receptor complex, at which point they bind to Smad4 and translocate to the nucleus 
(Glick, 2004). R-Smads and Smad4 shuttle back and forth between the nucleus and 
cytoplasm (Derynck and Zhang, 2003). 
Upon translocating to the nucleus, Smad complexes regulate transcription of 
target genes through physical interaction and functional cooperation with DNA-binding 
factors or coactivators such as CREB-binding protein (CBP) and p300 (Derynck and 
Zhang, 2003). Positive and negative regulation of transcription occurs with the 
cooperation of other DNA binding proteins and transcription factors at both the Smad 
binding elements (SBE) in the promoter regions of target genes and at the binding sites 
for other transcription factors (Derynck and Zhang, 2003). 
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Figure 7: R-Smad activation is regulated by receptor interacting proteins and 
Smad617. 
Interestingly, activation of R-Smads by type I receptor kinases is inhibited by 
Smad6 or Smad7 (Derynck and Zhang, 2003). In contrast to R-Smad expression, 
expression of the inhibitory Smad6 or Smad7 is highly regulated by extracellular signals 
(Derynck and Zhang, 2003). Induction of Smad6 and Smad7 expression by BMP and 
TGF-P respectively represents an auto-inhibitory feedback mechanism for ligand-induced 
signaling (Massague et al., 2000; Itoh et al., 2000; Moustakas et al., 2001). Activation of 
EGF receptor and possibly other tyrosine kinase receptors, interferon-y (INF-)I) signaling 
through Stat (signal transducer and activator of transcription) proteins, and activation of 
NF-KB by tumor-necrosis factor-a (TNF-a), also induce Smad7 expression, which leads 
to inhibition of TGF-P signaling (Massague et al., 2000; Itoh et al., 2000; Moustakas et 
al., 2001). 
1.6.5. TGF-$ signaling through Smad Independent Pathways 
Other proteins can associate with type I or type I1 receptors and regulate TGF-P 
ligand signaling without the direct effect of Smad activation. The activated receptor 
complexes activate non-Smad signaling pathways, such as TAKlNEKK-1, Ras, RhoA, 
PP2A signaling pathways (Derynck and Zhang, 2003). 
1.6.6. TGF-8 and EMT 
TGF-P1 is a ubiquitous cytokine that was originally named for its ability to 
transform normal fibroblasts in culture. Subsequently, TGF-PI was found to inhibit 
growth of normal epithelial cells, although it was also discovered that TGF-P1 could 
induce tumor cells to proliferate and promote an invasive phenotype and the ability to 
metastasize by mediating changes in the cytoskeletal architecture, which is known as 
EMT (Massague et al., 2000). Autocrine TGF-fl expression by tumorgenic cells induces 
matrix degradation, downregulates basement membrane components, and cell-cell 
adhesion molecules; such as E-cadherin, and induces an invasive, motile phenotype 
(Glick, 2004). 
It has been shown that TGF-P can induce morphological changes characteristic of 
EMT in normal and transformed mammary epithelial cells in culture (Oft et al., 1996; 
Miettinen et al., 1994). Furthermore, these experiments have also shown that this 
cytoskeletal reorganization is accompanied by the downregulation of adhesion and 
cytoskeletal proteins. such as E-cadherin and keratins, and induce de novo expression of 
the mesenchymal intermediate filament protein, vimentin (Oft et al., 1996; Miettinen et 
al., 1994). Since these initial experiments, TGF-P-induced EMT has also been reported 
in epidermal squamous cell carcinoma (Portella et al, 1998), in ras-transformed 
mammary carcinoma cells (Oft et al., 1996) and in ovarian adenosarcoma cells (Kitagawa 
et al., 1996). 
1.6.7. TGF-B Stimulates Angiogenesis 
As mentioned earlier (section 1.1), tumor angiogenesis is critical for tumor 
growth and invasion because this process facilitates the delivery of nutrients and oxygen 
to the tumor cells allowing sustained, rapid growth. The mechanism of angiogenesis 
simulation by TGF-PI is a combination of direct and indirect effects. Directly, TGF-P 
induces the expression of angiogenesis-inducing vascular endothelial cell growth factor 
(VEGF) (Pertovaara et al., 1994). TGF-P also can directly induce capillary formation of 
the endothelial cells cultured on a collagen matrix (Madri et al, 1998). Indirectly, TGF-P 
induces expression of the metalloproteases MMP-2 and MMP-9, as well as 
downregulation of tissue inhibitor metalloproteases (TIMPs) in tumor and endothelial 
cells, thus providing a protease-rich microenvironment that is conducive to the enhanced 
migration and invasion of active endothelial cells (Hagedorn et al., 2001). 
1.6. Epidermal Growth Factor 
1.6.1. Epidermal Growth Factor Introduction 
Epidermal Growth Factor Receptor (EGFR) is a receptor tyrosine kinase that is 
overexpressed in a number of human epithelial malignancies, including carcinomas of the 
lung, colon, ovary, bladder, and head and neck (Bishop and Weinberg, 1996). EGFR 
stimulates several properties that are critical for tumor progression, including 
proliferation, cell motility, cell adhesion, invasion, cell survival, and angiogenesis 
(Grandis and Sok, 2004). 
EGFR is a 170-kDa plasma membrane glycoprotein containing an extracellular 
ligand-binding domain, a single transmembrane domain, an intracellular domain with 
intrinsic tyrosine activity, and a C-terminal tail that contains specific tyrosine containing 
sequences that become binding sites for SHZcontaining signaling proteins upon 
phosphorylation. EGFR is one of a family of four structurally similar receptors that make 
up the erbB family. These receptors show homology in their kinase domains but are 
different in their extracellular regions and C-terminal tails. The erbB family of receptors 
are widely expressed in a variety of tissues and regulate different functions, including 
mitogenesis, differentiation, and cell survival and can undergo homo- (thick arrows) or 
heterodimerization (thin arrows) both constitutively and in response to the presence of 
specific ligands resulting in the potential to activate many signaling pathways (Grandis 
and Sok, 2004). 
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Figure 8: EGFR Signaling Pathway. 
Specificity of signaling is generated, at least in part, through the range of ligands 
and the intracellular protein-protein interactions that occur downstream of these erbB 
receptors. The selective activation of the signaling transduction pathways (yellow boxes) 
depends on the various arrangements of the ligand-erbB engagement, tyrosine 
phosphorylation, and subsequent receptor dimerization combinations beneath the cell 
surface (Grandis and Sok, 2004). In addition, for example, several ligands bind to 
EGFRIerbBl, including epidermal growth factor (EGF), transforming growth factor- 
alpha (TGF-a), and amphiregulin (Grandis and Sok, 2004). 
1.7.2. Epidermal Growth Factor and Head and Neck Cancer 
The up-regulation of EGFR expression and activity has been described in a 
number of epithelial tumors, including HNSCC (Howell and Grandis, 2005). 80-100% of 
head and neck tumors express EGFR (Grandis et al., 1998). Furthermore, EGFRIerbBl, 
erbB2, and erbB3 have each been independently correlated with the presence of nodal 
metastases and a shortened length of survival (Do et al., 2004; Xia et al., 1999). Studies 
have provided support for the prominent role of EGFR in controlling HNSCC invasion 
and metastasis and indicate EGFR as being one of the strongest predictors of survival and 
locoregional relapse (Ang et al., 2002; Grandis et al., 1998). Upregulation of EGFR is 
thought to influence important steps in tumor invasion and metastasis by enhancing cell 
motility, regulating cytoskeletal changes, altering cell adhesion, and directing the 
production of matrix-degrading proteolytic enzymes though downstream signaling 
effector molecules such as phospholipase C gamma-1 (PLCy-1) and focal adhesion 
kinase, in addition to promoting angiogenesis (Khazaie et al., 1993). 
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Figure 9: Signal transduction elements important to HNSCC invasion and 
metastasis. (Howell and Grandis, 2005) 
1.7.3. Matrix Metalloproteinases in Head and Neck Cancer 
EGFR activation is known to increase activation of matrix metalloproteinase 
(MMPs), in particular MMP-9 (Howell and Grandis, 2005). MMP-9 belongs to the MMP 
family of zinc dependent endopeptidases, which have been associated with tumor cell 
invasion, metastasis, and tumor-induced angiogenesis (Fridman et al., 2003). In addition, 
the MMP family member pro-MMP-9, has been shown to be a key enzyme in tumor 
progression playing a significant role in tumor cell invasion and in angiogenesis (Fridman 
et al., 2003). As a secreted MMP, pro-MMP-9 is released into the extracellular 
environment by tumor and stroma cells, degrading both the ECM matrix and non-ECM 
proteins, thus participating in events that are required for tumor cell migration and tumor- 
induced angiogenesis (Fridman et al., 2003). 
An elevated EGFR level in HNSCC tumors correlates with the expression of 
MMP-2, MMP-3, MMP-7, MMP-9, and MMP-10 (Howell and Grandis, 2005). MMP-2 
and MMP-9 overexpression in tumor cells has been shown to correlate with invasion, 
metastasis, and poor prognosis (Kawata et al., 2002; Ikebe et al., 1999; Hong et al., 
2000). In addition, EGF has been shown to increase HNSCC invasion through a 
basement membrane substitute and upregulate the expression of MMPs in HNSCC cell 
lines, again with a significant upregulation of MMP-9 (0-Charoenrat et al., 2000). 
Further, studies have demonstrated a failure of MMP upregulation, migration, and 
invasion in HNSCC tumor cell lines on EGFR blockade (0-Charoenrat et al., 2000). 
Figure 10: MMP cascade of zymogen activation involved in pro-MMP-9 
activation. (Fridman et al., 2003) 
Pro-MMP-9 can be activated by several different MMPs, including MMP-3 
(Ogata et al., ! 992), MMP-2 (Fridman et al., 2003), and MMP13 (Knauper e? al., 1997. 
This cascade of zymogen activation is initiated by MTl-MMP located at the cell 
membrane and requires the activation of TIMP-2. With the generation of MMP-2 and 
MMP-13, it can activate pro-MMP-9 (Fridman et al., 2003). 
1.7.4. Phospholipase C Pamma (PLCy-1) and Head and Neck Cancer 
PLCy-I is a ubiquitously expressed phosphoinositide-specific phospholipase that 
is activated downstream of EGFR (Wells and Grandis, 2003). PLCy-1 is activated by 
many growth factors including EGF and is required for cell motility (Howell and 
Grandis, 2005). Since cell migration is critical for metastatic progression of tumor cells, 
it is thought that the overexpression of PLCy-1 in HNSCC could contribute to invasion 
and metastasis. Interestingly, PLCy-1 regulates cell motility in response to growth 
factors through the activation of actin-modifying proteins such as gelosin, and through 
the hydrolysis of phosphoinositide (43 bisphosphate (PIP2) into diacylglycerol (DAG) 
and inositol triphosphate (IP3), which are significant in the regulation of actin 
cytoskeletal alterations and adhesionlde-adhesion mechanisms (Wells and Grandis, 
2003). 
Increased total and phosphorylated PLCy-1 has been reported in HNSCC tumors 
compared with normal adjacent mucosa (Thomas et al., 2003). Furthermore, other 
studies have shown that inhibition of PLCy-1 signaling significantly reduces in vitro 
invasion through matrix barriers, suggesting that PLCy-1 plays a role in HNSCC invasion 
and metastasis (Thomas SM et al., 2003). Therefore, the upregulation of PLCy-1 is one 
downstream signal transducer that may mediate invasion and metastasis in HNSCC and 
other epithelial tumors. 
1.7.5. EGFR and Focal Adhesion Kinase 
Focal Adhesion Kinase (FAK) is upregulated in several tumor types, including 
HNSCC (Aronsohn et al., 2003). FAK is an intracellular nonreceptor tyrosine kinase, 
which associates with integrins within cellular structures referred to as focal adhesions 
and becomes phosphorylated and activated during integrin-mediated cell adhesion to 
extracellular matrix (ECM) ligands (Howell and Grandis, 2005). Furthermore, FAK is an 
important mediator of growth factor signaling, cell proliferation, cell survival, and cell 
migration (McLean et al., 2005). 
FAK expression and its activity are frequently correlated with malignant or 
metastatic disease and poor patient prognosis (Recher et al., 2004; Schlaepfer et al., 
2004). Previous studies have shown an association between the enhanced expression and 
phosphorylation of FAK and increased invasiveness and the metastatic ability in HNSCC 
cell lines (Schneider, et al., 2002; Kornberg, 1998). In addition, gains in the FAK gene 
copy number have been found in cells derived from head and neck cancer (Agochiya et 
al., 1999). 
Figure 1 1: Focal-adhesion kinase as a signal integrator. (McLean et al., 2005) 
FAK carries out protein-protein interaction adaptor functions at the sites of cell 
attachment to the ECM, which contributes to focal-adhesion and transmits adhesion- 
dependent and growth factor-dependent signals into the cell interior (McLean et al., 
2005). FAK integrates signals from extracellular cues, including growth-factor receptors 
and integrins, and from the upstream SRC-family kinases, to control and coordinate 
adhesion dynarnicslcell migration with survival signaling (McLean et al., 2005). 
Figure 12: Focal-adhesion kinase influences cell migration through additional 
molecular signaling pathways. (McLean et al., 2005) 
FAK mediated signaling events induce the expression of genes encoding MMPs 
(McLean et al., 2003). As stated previously (section 1.7.3), once the MMPs are secreted 
by the cell, they have the ability to mediate the breakdown of surrounding ECM 
substrates and promote cell invasion (McLean et al., 2003). 
1.7.6. EGFR and Angiogenesis 
EGFR activation has been linked with an increase in angiogenesis and metastasis. 
It has been proposed that EGFR-mediated signaling upregulates the expression of VEGF 
and interleukin-8 (IL-8) by inducing downstream signaling pathways, which promote the 
coactivation of transcription factors for IL-8 and VEGF expression, including nuclear 
factor kappaI3 (NF-KB) and activator protein-1 (AP-1) (Bancroft et al., 2001). VEGF and 
IL-8 are proangiogenic factors that are upregulated and coexpressed in HNSCC tumors, 
and are associated with aggressive tumor growth and decreased survival rate (Eisma et 
al., 1999; Bancroft et al., 2001). AP-1 is thought to activate the transcription of both 
VEGF and IL-8, whereas, NF-KB activates IL-8 transcription as well as being important 
for the expression of growth-regulated oncogene-1 (GRO-I), which is a neutrophil 
chemoattractant whose increased expression has also been associated with HNSCC tumor 
angiogenesis and metastasis (Bancroft et al., 2001; Shintani et al., 2004) 
1.8. Aims of the Current Studs 
1. To determine how vimentin expression differs in primary and metastatic HNSCC. 
2. To determine if vimentin expression is modulated by the invasion-inducing 
transforming growth factor P (TGF-P) and/or epidermal growth factor (EGF). 
3. To determine if vimentin expression contributes to the invasive phenotype of 
metastatic HNSCC cells. 
4. To determine what mechanisms regulate vimentin gene transcription in metastatic 
HNSCC. 
2. Paper Introduction 
In cancer progression, epithelial to mesenchymal transition (EMT) is associated 
with tumor invasiveness, and intravasation and extravasations of metastatic cells 
(reviewed in Thiery, 2002). For example, many invasive and/or metastatic tumors are 
characterized by partial or complete EMT, in which the epithelial phenotype of tight 
intercellular junctions and polarity across the epithelial layer is replaced by a more 
mesenchymal phenotype with reduced cell-cell adhesions, altered shape, expression of 
mesenchymal cellular markers, and enhanced cell motility (Ruiz and Gunthert, 1996; 
Boyer et al., 2000; Wu et al., 2004). EMT is now being recognized as a hallmark of 
tumor progression, characterizing invasive and metastatic carcinomas (Birchmeier et al., 
1996). 
It has been suggested that the intermediate filament protein, vimentin, may be a 
potential diagnostic marker for the initial progression of cells from a localized epithelial 
lesion to become migratory, metastatic tumor cells (Gilles et al., 1996). There are 
approximately fifty different types of intermediate filament protein that are categorized 
into five subtypes, with vimentin belonging to type 111. Vimentin is normally expressed 
in the cells of mesenchymal origin; therefore, it serves as an appropriate marker for the 
transition of carcinoma cells from an epithelial to mesenchymal phenotype. 
Vimentin displays a complex pattern of gene expression. Eukaryotic gene 
regulation studies suggest that multiple binding motifs are located within the human 
vimentin promoter, some of which bind factors that enhance gene expression and others 
that repress expression. These include: a TATA-box and several positive regulatory 
elements such as eight GC-boxes (Rittling and Baserga, 1987); a PEA3 site (Chen et al., 
1996); an NF-KB site (Lilienbaum and Paulin, 1993); a A19 site (Salvetti et al., 1993); a 
PS element (Wieczorek et al., 2000); two tandem AP-1 binding sites (Rittling et al., 
1989); a p-catenin site (Gilles et al., 2003); an antisilencer (ASE) element (Izmailova and 
Zehner, 1999); and a proximal silencer (PS) element (Salvetti et al., 1993). 
It has been shown that binding of the GC-box (at position -64 to -55) is critical 
for the regulation of human vimentin gene expression (Izarnailova et al., 1999). The c- 
Jun protein synergizes with the activator protein spl to enhance vimentin gene expression 
by binding to the GC-box1 (Wu et al., 2003). In addition to direct interaction with spl, 
cJun also binds to tandem AP-1 sites located upstream in the vimentin promoter in order 
to activate vimentin gene expression (Wu et al., 2003). Interestingly, ZBP-89, a known 
Kruppel-like zinc finger protein, is capable of interacting with spl and inhibiting the 
activation of the vimentin promoter (Zhang et al., 2003). Furthermore, the PS silencer 
element located between positions -319 and -261 binds ZBP-89, which represses gene 
transcription (Wieczorek et al., 2000). An antisilencer element, ASE, located further 
upstream (position -757) binds Stat3 and can overcome ZBP-89-dependent repression 
(Wu Y., 2004). Interestingly, recent findings have shown that Stat3 is constitutively 
activated in many metastatic tumors from a range of cell lineages (Bromberg et al., 1999; 
Bromberg et al., 2001; Garcia et al., 2001; Zajchowski et al., 2001; Levy and Darnell, 
2002). 
EMT can be induced by a variety of growth factors, including EGF and TGF-P 
(Miettinen et al., 1994; Bhowmick et al., 2001 ; Piek et al., 1999; Lu et al., 2003), and a 
synergistic effect on EMT has been observed following treatment with a combination of 
EGF and TGF-P (Grande et al., 2002). Interestingly, at the transcriptional level, EGF 
and TGF-P activate different binding sites on the vimetin promoter, EGF targeting the 
transcriptional binding protein, spl  binding to GC-box and TGF-P targeting the tandem 
AP-1 sites. In addition, EGF and TGF-P synergistically activate the transcriptional 
binding protein, Stat3, which binds to the ASE site on the vimentin promoter. 
Squamous cell carcinoma of the head and neck region (HNSCC) is the sixth most 
common malignancy worldwide. HNSCC lesions are locally aggressive and frequently 
undergo EMT, with metastasis to local and regional lymph nodes, which dramatically 
decreases the likelihood of a good clinical outcome. Thus, prevention, early detection, 
and the ability to prevent invasion and regional metastasis of the primary lesion are major 
goals to combat this disease. In order to develop a model system in which to investigate 
genetic, biochemical, and biological changes that occur during metastatic progression of 
head and neck squamous cell carcinoma, we established HN4 cells from a primary tongue 
tumor and HN12 cells from a synchronous lymph node metastasis and characterized their 
behavior (Yeudall et al., 2005). Metastasis-derived HN12 cells are invasive in vitro and 
tumorigenic in vivo, whereas HN4 cells are not. In addition, invasion of HN12 cells is 
enhanced by epidermal growth factor (EGF; Yeudall et al., 2005) and by transforming 
growth factor P (TGF-P; Miyazaki et al., in press). Comparing global gene expression 
profiles of HN4 and HN12 cells revealed that vimentin gene expression was found to be 
upregulated in metastasis-derived HN12 cells (Miyazaki et al., 2005). 
Determining the mechanisms of vimentin gene regulation will contribute to our 
.understanding of processes involved in EMT and might, potentially, provide insight into 
factors controlling tumor cell invasiveness. In the present study, we have investigated 
regulation of vimentin expression by EGF and TGF-P in metastatic HN12 cells, and the 
contribution of vimentin overexpression to the cellular phenotype. 
3. 'Materials and Methods 
3.1 Cell, Cultures 
HN4 cells were derived from a primary squarnous cell carcinoma of the head and 
neck region, while HN12 was derived from a nodal metastasis in the same patient from 
whom the HN4 cells originated. HNSCC cell lines were cultured in DMEM (Invitrogen 
Corporation, NY) supplemented with 10% fetal bovine serum (FBS), and penicillin - 
streptomycin (IOuglml) (Mediatech, Cellgro) in the presence of puromycin (lpglml) at 
37°C in 90% air/lO% C02. 
3.2 Plasrnids 
Targeting sequences for vimentin-shRNA plasmids were designed using web- 
based software. 
( h t t p : / l w w w . a m b i o n . c o r n / t e c h l i b / m i s c / s i ~ )  (Ambion, Austin, TX) and the 
sequences for senselantisense oligonucleotides are as follows: vimentin-shRNA sense, 5'- 
GATCCGTAAGCACTAGCCACGACACTTTTCAAGAGAGTGTCGTGGCTAGTGC 
TTATTCTTTTTTTCTAGAG-3'; antisense, 5'- 
AATTCTCTAGAAAAAAAGAATAAGCACTAGCCACGACACTCTCTTGAAAAGT 
GTCGTGGCTAGTGCTTAG-3'. Oligonucleotides for non-targeting controls were 
sense, 5'- 
GATCCGGCATGTACTAGCCTAAGCGTTTTCAAGAGACGCTTAGGCTAGTACA 
TGCTTCTTTTTTTCTAGAG-3'; antisense, 5'- 
AATTCTCTAGAAAAAAAGAAGCATGTACTAGCCTAAGCGTCTCTTGAAAACG 
CTTAGGCTAGTACATGCG-3', respectively. Complimentary oligonucleotides were 
diluted ta..l Ow, mixed togethPs, boiled for 5 min in a water bath, and leftaxemight at 
ambient temperature. Annealed oligonucleotides were ligated into the pSIREN-Retro-Q 
retroviral vector (BD Biosciences Clontech, Palo Alto, CA) digested by BamHI and 
EcoRI. 
For chloramphenicol acetyltransferase (CAT) assays, 5'-deleted sequences 
representing nucleotides -757/+72, -749/+72, -719/+72, or -216/+72 or point-mutated 
sequences (-747/+72mAPl) of the human vimentin promoter were cloned upstream of 
the CAT gene as described (Izmailova and Zehner, 1999; Izmailova et al., 2000; 
Wieczorek et al., 2000; Wu et al., 2004). Promoter sequences are indicated in Figure 17 
A and B. 
3.3 Generation of Cell Lines that Stably Express shRNA Plasmids 
HN12 cells containing vimentin shRNA or non-targeted control plasmids were 
prepared as follows. HN12 cells were plated in 10cm tissue culture dishes at 60% 
confluency, transfected with 3pg of plasmid DNA using TranslT Keratinocyte Reagent 
(Mirus Bio Corporation, Madison, WI). 48h later, cells were selected in the presence of 
lpglrnl puromycin. Individual puromycin resistant colonies were isolated and 
propagated. 
3.4 Cell Transfection and CAT Assay 
HN12 cells -were transfected using Amaxa Nucleofector Kit (Amaxa hc., 
Gaithersburg, MD) according to the manufacturer's recommended protocol. Cells were 
plated (5 x lo5) in one well of a six-well plate and transfected with 1.5pg of plasmid 
DNA and 0.5pg GFP in order to serve as an internal control for transfection efficiency. 
The amount of each plasmid was optimized by transfecting different amounts of plasmid 
DNA. After transfection (48h), cell lysates were prepared and CAT Elisa assays were 
performed according to the provided protocol by Roche Diagnostic Corporation 
(Indianapolis, IN). Alternately, after 24h transfection, cells were serum starved or treated 
with the appropriate growth factor for 24h. Western blot analysis was performed using 
GFP B-2 specific antibody (Santa Cruz Biotechnology, Santa Cruz, California). 
3.5 Western Blot Analvsis 
Cell extracts were prepared from HNSCC, parental vimentin shRNA, and control 
transfected HN12 cell lines after 48h serum starvation or 24h serum starvation followed 
by treatment with growth factors, EGF, TGF-P, or TGF-P and EGF for 24h. Cells were 
washed and resuspended in 5 0 0 ~ 1  of ice-cold Lysis buffer (25 rnM HEPES, pH 7.5,0.3M 
NaCl, 1.5mM MgC12, 0.2mM EDTA, 0.5mM DTT, 1% Triton X-100, 0.1% SDS, and 
1rnM PMSF, and 0.4M NaCl). Cleared lysates were combined with SDS sample buffer, 
denatured for 5 min at 100 "C, and resolved by 10% SDS-PAGE. Fractionated proteins 
were electroblotted to PVDF membranes (Irnmobilon-P, Millipore Corporation, Bedford, 
MA) overnight. The membranes were then blocked with 4% non fat dried milk in 0.03% 
tween-TBS (T-TBS) for l h  at room temperature, washed with 0.03% T-TBS three times, 
and incubated with. anti-vimentin monoclonal antibody 1 : 1000 diluted in 4% non fat dried 
milk for l h  at room temperature. Membranes were then washed with 0.03% T-TBS three 
times, incubated with horseradish peroxidase-conjugated (HRP) goat anti-mouse 
monoclonal antibody 1: 10000 diluted in blocking buffer for 1 h at room temperature, and 
washed four times in 0.03% T-TBS at room temperature. The specific antigen-antibody 
interactions were detected using enhanced chemiluminescence (ECL Plus, Amersham 
Biosciences, Piscataway, NJ). 
3.6 Imrnunofluorescence 
Cell lines (2 x lo5) were plated on coverslips in twelve-well plates and allowed to 
attach for 24h. Cells were then serum starved for 48h, washed, and fixed with cold 
methanol at -20°C for 20 min. Cells were washed with PBS for 5 min, and blocked in 
5% BSA, 0.1% Triton-X 100 in PBS for l h  at room temperature. Cells were incubated 
with monoclonal anti-vimentin antibody (Sigma, St. Louis, MO) 1:250 diluted in 
blocking buffer overnight at 4°C. The cells were then washed three times with PBS and 
incubated with a FITC-conjugated anti-mouse antibody at 1:500 dilution in 5% BSA, 
0.1% Triton-X 100 in PBS for lh  at room temperature. Coverslips were mounted on a 
microscope slide and viewed with a Zeiss Axiovent 200 inverted fluorescence 
microscope. 
3.7 Immunocytochemistry 
Cell lines were plated on coverslips in twelve-well plates at 2 x 10~cells/well. 
After 24h culture, cells were washed twice with PBS and serum starved for 48h or serum 
starved for 24h and treated with EGF, TGF-P, or EGF and TGF-P for 24h. Cells were 
washed, fixed with cold methanol at -20 OC for 20 rnin, washed with PBS for 5 min, and 
blocked in 5% BSA, 0.1% Triton-X 100 in PBS for lh. Cells were incubated with anti- 
vimentin antibody as described above overnight at 4OC. Cells were then washed three 
times with PBS and incubated with HRP-conjugated goat anti-mouse antibody (Cappel, 
ICN Pharmaceuticals Inc., Aurora, OH) 1500 diluted in blocking buffer for l h  at room 
temperature and washed three times in PBS. The specific antigen-antibody interactions 
were detected using a DAB staining kit (Vector Laboratories, Burlingame, CA) according 
to the manufacturer's instruction. Coverslips were mounted on microscope slides and 
viewed under an Olympus CK40 microscope. 
3.8 Migration Assay 
Subconfluent lOcm plates of cell lines were detached using HBSS / 5rnM EDTA / 
25rnM Hepes pH 7.2 solution (Mediatech, Cellgro). The cells were then washed twice in 
DMEM/O.l% BSA and resuspended in DMEM/O.l% BSA at a concentration of 1 x lo6 
cells/rnl. Cells (1x10~) were added to the upper chamber of a 8pm pore size Transwell 
(Corning Incorporated, Beverley, MA) and allowed to migrate for 6h. EGF (lOngIml) 
-, 
(Austral Biological, San Roman, CA) in DMEM/O.l% BSA was added to the lower 
chamber of each well as a chemoattractant. The cells were then fixed in 100% methanol, 
stained with 0.1% crystal violet in O.1M sodium borate pH 9, 2% EtOH overnight at 
ambient temperature, and destained in ddH20. The non-migratory cells on the upper 
surface of the membrane were removed with cotton swabs and mounted on a microscope 
slide. Migrated cells were counted in five randomly selected high power fields per 
membrane using an Olympus CK40 microscope. 
3.9 Invasion Assay 
Subconfluent lOcm plates of the HNSCC and vimentin stably transfected HN12 
cell lines were detached using Cellstripper (Mediatech, Cellgro). The cells were then 
resuspended in DMEM supplemented with 0.1% Bovine Serum Albumin (BSA) and 
plated (2 x 10~ /400~1)  in the upper chamber of Matrigel-coated Transwell inserts (pore 
size 12p.m) (Corning Incorporated, Beverley, MA). In addition, 500~1 of DMEM 
supplemented with 0.1% BSA with lOng/ml EGF was added to the lower chamber of 
each well. The cells were allowed to invade for 16h and then fixed with 0.5ml of 5% 
glutaraldehyde in l x  PBS for 10 min at ambient temperature and washed three times in 
ddH20. The cells were stained with 0.1 % crystal violet in O.1M sodium borate pH 9, 2% 
EtOH for 20 min at room temperature and then washed three times with ddH20. The 
non-invading cells on the upper surface of the membrane were removed with cotton 
swabs and membranes were mounted on microscope slides. Invading cells were counted 
in five randomly selected high power fields per membrane using an Olympus CK40 
microscope. 
3.10 Proliferation Assay 
Cell lines were trypsinized using 0.25% Trypsin-EDTA (Invitrogcn Corporation, 
NY). The cells were then resuspended in complete growth medium containing lpglml 
puromycin, counted, and plated 2 x 10' cells/well in twenty four-well plates. After 24h 
of culture, triplicate wells were counted daily for eight consecutive days using a 
hemacytometer. 
3.11 qRT-PCR 
To design the oligonucleotide primers for quantitative RT-PCR, we utilized the 
Primerbank database 
(ht tp: / /pga.mgh.harvard.edu/primerbank/)  (Wang and Seed, 2003). We 
initially screened several set of primers by running PCR experiments to confirm that 
these produced PCR products of the predicted size. The primers used were as follows: 
Vimentin-qPCR sense, 5'-CTCCTCCCCCTGTCACATAC-3'; Vimentin-qPCR 
antisense, 5'-TGATTGGCATCAGGACCGTTG-3'. Total RNA was extracted from 
lOcm plates using 8ml of T r i a l  reagent after washing with PBS twice, and 3pg of total 
RNA was converted to cDNA using Superscript I11 (Invitrogen Corporation) according to 
the manufacturer's instructions. Real-time quantitative PCR was performed using a 
Lightcycler (Roche Diagnostics, Indianapolis, IN) with fluorescence signal detection 
(SYBR green) after each cycle of amplification as previously described (Deb et al., 
2002). Product-specific amplification was confirmed by a melting curve analysis and 
agarose gel electrophoresis analysis. Quantification was focused on the log-linear phase 
of amplification above the baseline using the Lightcycler software. The calculated 
cDNA copy number in each sample was derived from an extrapolated crossing point of a 
mathematically derived line extending from the exponential phase of amplification in a 
plot of fluorescence intensity (SYBR green) versus cycle number. For each reaction, 
diluted amounts of known templates provided quantitative standard curve reactions from 
which cDNA copy number could be determined. GAPDH was used as a housekeeping 
gene to normalize the initial content of total cDNA in the samples. 
4. Results 
4.1 Upregulation of Vimentin in HN12 cells. 
The derivation of the metastatic HN12 squamous carcinoma cell line and the non- 
metastatic HN4 cell line has heerl described previously. When comparing the gene L 
expression pattern of these two cell lines using cDNA microarrays (Miyazaki et al., 
2005), we discovered overexpression of vimentin in HN12 cells. In order to confirm this 
finding, we prepared total cellular RNA from serum-deprived HN4 and HN12 cells, 
reverse-transcribed this and performed quantitative real-time PCR (qRT-PCR) on the 
cDNA template using vimentin-specific primers. As shown in Fig. 13A (upper panel), 
vimentin RNA is around 4-fold more abundant in HN12 cells compared to HN4. Further, 
we confirmed vimentin overexpression in HN12 cells by western blot analysis of total 
cellular protein lysates. Whereas vimentin was readily detectable in HN12 cell lysates, 
no signal was obtained with HN4 lysates (Fig. 13A, lower panel). In addition, 
immunocytochemical staining (Fig. 13B) showed strong vimentin ubiquitous staining in 
HN 12 cells, whereas this was absent in HN4 cells. Irnmunofluorescence microscopy (Fig 
13C) revealed a dense network of vimentin filaments in the HN12 cells. These data 
confirm that expression of vimentin is upregulated in cells at a later stage of tumor 
progression and confirm the microarray findings. 
vimentin 
Figure 13A: Total RNA was extracted from subconfluent cultures, reverse-transcribed to 
generate cDNA and subjected to real-time quantitative PCR as described in 'Materials 
and Methods'. The relative expression ratio is defined as the expression levels of 
vimentin to that of an internal standard, GAPDH. Assays were carried out in triplicate 
and means+lSD are indicated. Parallel cultures, similarly treated, were used for western 
blot analysis of vimentin expression. After 48h of serum deprivation, total cell protein 
extracts were prepared as described in 'Materials and Methods' and analyzed for 
vimentin expression (top panel). Levels of p-actin were determined as a loading control 
(lower panel). 
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Figure 13B: Analysis of vimentin expression in HN4 and HN12 cells using 
immunocytochernistry. Cells were cultured on glass coverslips for 24h, serum deprived 
for 48h, and fixed as described in 'Materials and Methods'. Cells were incubated with 
anti-vimentin antibody (or mouse IgG as control) overnight and detected with HRP- 
conjugated goat anti-mouse antibody and DAB. Images were viewed under a light 
microscope. 
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Figure 13C: Analysis of vimentin expression in HN4 and HN12 cells using 
imrnunofluorescence. Cells were cultured on glass coverslips for 24h, serum deprived for 
48h, and fixed as described in 'Materials and Methods'. Cells were incubated with anti- 
vimentin antibody (or mouse IgG as control) overnight then incubated with a FITC- 
conjugated anti-mouse antibody for lh  and counterstained with DAPI. Images were 
viewed using a fluorescence microscope. 
4.2 EGF and TGF-fl Synergize to Increase Vimentin Expression. 
Epidermal growth factor (EGF) and transforming growth factor P (TGF-P) are 
thought to contribute to tumor metastasis through a number of mechanisms, including 
enhanced cell migration and epithelial to mesenchymal transition (EMT), and have been 
demonstrated to enhance migration and invasion of HN12 cells (Yeudall et al., 2005; 
Miyazaki et al., in press). To determine whether either of these growth factors resulted in 
upregulation of vimentin expression, we treated HN12 cells with EGF or TGF-P, or a 
combination of both, then performed qRT-PCR using cDNA prepared from HN12 RNA 
as a template. As shown in Fig. 14A (upper panel), vimentin RNA was increased by 
around three-fold in TGF-P treated cells over basal expression levels, around five-fold 
with the addition of EGF, and a synergistic seven-fold increase when cells were treated 
with a combination of TGF-P and EGF. Interestingly in HN4 cells, we observed a 
similar trend of vimentin upregulation but, even with the addition of both EGF and TGF- 
p, expression was considerably lower than basal levels in HN12 cells. 
As we had found that EGF and TGF-P elevated levels of vimentin RNA in HN12 
cells, we sought to determine whether this was reflected by an increased abundance of 
vimentin protein. Therefore, we treated cells with growth factors as before, prepared 
total cellular protein extracts, and performed western blot analysis. Vimentin protein 
expression was undetectable in HN4 cells by our assay (Fig. 14A, lower panel), even 
with addition of growth factors. However, increased levels of vimentin protein were 
detected in TGF-P and EGF-treated HN12 cells, concomitant with the previously 
observed rise in vimentin RNA. Further, we analyzed vimentin expression in growth 
factor-treated cells by irnrnunocytochernical staining. HN12 cells displayed an 
ubiquitous distribution pattern of vimentin throughout the cell, which was further 
enhanced, with the addition of EGF and TGF-P (Fig 14B). Taken together, EGF and 
TGF-P Ireatment result in increased vimentin RNA and protein levels in HN12 cells, 
suggesting that both growth factors may play a role in EMT in this system. Further, EGF 
and TGF-P stimulate expression of vimentin RNA in primary tumor-derived HN4 cells 
with a trend similar to that seen in HN12 cells; however RNA levels are extremely low 
and vimentin protein is undetectable. 
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Figure 14A: Cells were cultured in the presence or absence of growth factors as indicated. 
Total RNA was extracted from subconfluent cultures, reverse-transcribed to generate 
cDNA, and subjected to quantitative real-time PCR as described in 'Materials and 
Methods'. The relative expression ratio is defined as level of vimentin expression to that 
of an internal standard, GAPDH. Assays were carried out in triplicate and means+lSD 
are indicated. Parallel cultures, similarly treated, were used for western blot analysis of 
vimentin expression as described in 'Materials and Methods' and as described in Figure 1. 
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Figure 14B: Immunocytochernical analysis of vimentin expression in HN4 and HN12 
cells with the addition of TGF-P and EGF. Cells were cultured on glass coverslips for 
24h, then serum deprived for 48h or serum deprived for 24h and treated with EGF, TGF- 
p, or EGF andfor TGF-P for 24h and then fixed as described in 'Materials and Methods'. 
Cells were incubated with anti-vimentin antibody (or mouse IgG as control) overnight 
and detected with HRP-conjugated goat anti-mouse antibody and DAB. Images were 
viewed under a light microscope. 
4.3 Tar~eted Suppression of Vimentin Expression. 
In order to study the contribution of vimentin expression to the biological 
properties of HN12 cells, we used RNA interference (RNAi) technology to reduce 
vimentin levels. Thus, HN12 cells were stably transfected with a plasmid that directs 
synthesis of a vimentin shRNA, or a non-targeting control (NTC) plasmid, and colonies 
selected for resistance to puromycin and screened for vimentin expression by qRT PCR, 
western blot analysis, and immunofluorescence. As shown in Fig 15A, qRT-PCR 
identified a ten-fold minimum decrease in vimentin expression in HNl2-shVim clones 
compared to the HN12-NTC control cells. In addition, this reduction of vimentin 
expression was confirmed by imrnunofluorescence microscopy, which showed a 
cytosolic distribution pattern of staining in the HN12-NTC clones and the absence of 
staining in the HN 12-shVim clones (Fig 15B). Furthermore, vimentin expression was 
undetectable by western blot analysis in either of the two HNl2-shVim clones compared 
to the parental HN12 cell line and HNlZNTC clones (Fig. 15A). Taken together, these 
data indicate that vimentin expression is substantially reduced in HN12-shVim clones 
compared to non-targeting controls and, thus, may be suitable for investigating the 
contribution of vimentin expression to the biological phenotype of metastatic HN12 cells. 
Immunocytochemical staining demonstrated a significant increase of vimentin 
expression in HN12-NTC compared to the HN12-shVim clones (Fig 15C). With the 
addition of EGF and TGF-0, the expression pattern of vimentin in HN12-shVim cells 
(Fig. 15C) is similar to the pattern seen in HN4 cells (Fig. 14B). Interestingly, there is a 
slight increase in vimentin expression with the addition of either EGF or TGF-P 
individually and an even greater increase with the addition of both growth factors 
together. However, even with the addition of both growth factors to the HNl2-shVim 
cell line, the expression of vimentin is considerably lower then the basal expression of 
vimentin in HN12 and HN12-NTC cells. Further, we confirmed these results using 
western blot analysis of total cellular protein lysates (Fig 15C). 
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Figure 15A: Cells lines that stably express vimentin shRNA or non-targeting control 
plasrnids were generated as described in 'Materials and Methods'. Total RNA was 
prepared from subconfluent cultures, reversed transcribed, and the resultant cDNA 
subjected to quantitative real-time PCR as described above. The relative expression ratio 
is defined as the expression level of vimentin to that of an internal standard, GAPDH. 
Assays were carried out in triplicate and means+lSD are indicated. Western blot analysis 
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of vimentin expression (top panel) and actin as a control was carried out as described 
above (lower panel). 
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Figure 15B: Cells were plated on glass coverslips for 24h, serum deprived for 48h and 
then fixed as described in 'Materials and Methods'. Cells were incubated with anti- 
vimentin antibody (or mouse IgG as control) overnight followed by FITC-conjugated 
goat anti-mouse antibody. Cells were counterstained with DAPI and detected using a 
fluorescence microscope. 
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Figure 15C: Cells containing vimentin shRNA or non-targeting control plasmids were 
cultured on coverslips for 24h, serum starved for 48h, and fixed as described in 
blot 
'Materials and Methods'. Cells were incubated with anti-vimentin antibody (or mouse 
IgG as control) overnight then incubated with a HRP-conjugated anti-mouse antibody for 
Ih. Images were viewed using a light microscope. Western blot analysis of vimentin 
expression (top panel) and actin as a control was carried out on parallel cultures as 
described above (lower panels). 
4.4 Vimentin Overexpression is Important for Biological Properties of HN12 Cells. 
Squamous carcinoma cells tend to grow more rapidly andlor fail to die at a normal 
rate. In addition, these cells can also invade surrounding tissue and metastasize. Many 
cells undergo EMT as a feature of tumor progression. Thus, in order to determine 
whether the mesenchymal cell marker, vimentin, contributes to the phenotype of HN12 
cells, we first compared the proliferation rate in culture of HNl2-shVim and HN12-NTC 
cells. Cells were seeded in quadruplicate in multi-well plates, then trypsinized and 
counted over an eight day period. As is apparent from Fig. 16A, HNl2-shVim clones 
exhibit a marked decrease in proliferation compared to the HN12-NTC cells, suggesting 
that vimentin may contribute to cell growth. Next, we compared the contribution of 
vimentin overexpression on the motility and invasiveness of HN12 cells using in vitro 
assays. As shown in Fig. 16B, downregulation of vimentin expression in HN12-shVim 
cell lines decreases migration in Transwell assays by four-fold in comparison to the 
HNl2-NTC control clones. Furthermore, in vitro invasion through Matrigel is markedly 
decreased in cells with lower expression of vimentin (Fig. 16C). Taken together, these 
data indicate a crucial role for vimentin in the proliferation and invasion of metastatic 
HN 12 squamous carcinoma cells. 
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Figure 16A: Cells (2 x lo3 per well) were plated in triplicate in 24-well plates and 
incubated under standard culture conditions as described in 'Materials and Methods'. 
Cells were trypsinized and counted daily for eight consecutive days. Values shown are 
meanskl SD. 
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Figure 16B: Cells from subconfluent cultures were detached in the absence of trypsin, 
washed, and plated in Transwell chambers as described in 'Materials and Methods' with 
EGF in the lower chamber to act as a chemoattractant. 6h later, migrated cells were 
stained and counted in 10 random high power fields. Data shown represent means+lSD. 
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Figure 16C: Cells from subconfluent cultures were detached in the absence of trypsin, 
washed, and plated in Matrigel-coated Transwell chambers as described in 'Materials and 
Methods'. 16h later, invading cells were stained and counted in 10 random high power 
fields. Data shown represents means21 SD. 
4.5 Regulation of Vimentin Promoter Activity in HN12 Cells by EGF and TGF-B. 
How the vimentin gene is regulated is important for understanding the 
relationship between gene expression and tumor progression which, based on our data 
presented above, could ultimately contribute to controlling the invasiveness in some 
tumors. Therefof?, we used vimentin promoter fragments, which begin at +72 and extend 
to -261, -719, -749, and -757 to investigate which transcription factor binding sites 
mediate upregulation of vimentin expression in HN12 cells. These promoter fragments 
were cloned 5' to a CAT reporter gene and are shown in schematic form in Fig. 17A. 
The vimentin promoter sequence is shown in Fig. 17B. Plasmids encoding vimentin 
promoter-CAT sequences were transiently transfected into HN12 cells and CAT activity 
measured by ELISA assay following serum withdrawal (Fig. 17C). The 261CAT 
sequence containing the GC-boxl, PEA3 and NF-KB sites showed substantial activity 
under conditions of growth factor withdrawal. This activity was much reduced in cells 
transfected with the 719CAT plasmid, which contains two sites (PS and H4TF-1) that 
bind the ZBP-89 repressor protein. Moderate restoration of activity was achieved with 
the addition of two AP-1 binding sites in the promoter (749CAT), while further addition 
of the ASE site (757CAT) further increased promoter activity (Fig. 17C). Taken together, 
the data suggest that basal activity of the vimentin promoter in HN12 cells is mediated 
through ASE and AP-1 sites, as well as one or more of the GC-boxl, PEA3 and NF-KB 
sites. Furthermore, the data indicate that ZBP-89 repressor activity is high in these cells. 
Next, we examined vimentin promoter activity in the presence of EGF and TGF-P 
to determine the binding elements responsible for the increased vimentin expression 
observed by qRT-PCR, western blot analysis, immunocytochemistry, and 
immunofluorescence. Using the 757CAT sequence, we found that treatment of cells with 
either EGF or TGF-P stimulated promoter activity above that observed under conditions 
of serum withdrawal, while the presence of both growth factors further elevated CAT 
activity (Fig. 17D). In contrast, CAT activity in cells transfected with the 261CAT 
sequences (containing the GC-box, PEA3 and NF-KB sites) was maximal in the presence 
of EGF, which stimulated promoter activity by around 3-fold over basal conditions (Fig. 
17E). Treatment of these cells with TGF-P did not produce any significant increase in 
promoter activity. Surprisingly, addition of both growth factors simultaneously resulted 
in lower activity than with EGF alone (Fig. 17E), suggesting that TGF-P may antagonize 
the action of EGF on these promoter elements. However, in cells transfected with the 
749CAT plasmid, TGF-P produced an increase in promoter activity of around 2.5-fold 
over basal levels, whereas EGF had little effect (Fig. 17F). Similar to the results with the 
261CAT sequences, addition of both growth factors failed to produce a synergistic effect, 
implying that EGF antagonizes the TGF-P-mediated stimulation of the AP-1 sites. Taken 
together, the data suggest that EGF-dependent pathways target binding elements in the 
proximal vimentin promoter, while TGF-P is likely to act in an AP-1-dependent manner. 
Furthermore, both growth factors appear to synergize by stimulating promoter activation 
through the ASE site, suggesting involvement of Stat-dependent pathways in regulation 
of vimentin expression in HN12 cells. 
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Figure 17A: Regulatory elements [transcription factor binding sites] in the vimentin 
promoter. The relative position of regulatory elements previously reported to be present 
in the vimentin promoter is shown (top panel). 5'-deleted sequences or point-mutated 
sequences of the human vimentin promoter were cloned upstream of the CAT reporter 
gene as described in 'Materials and Methods'. * indicates site of point mutation. 
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-720 tttcctctgccaccgccgtctcgcaactcccgccgtccgaagctggactgagcccgttag 
-600 gaggcgcgggccggagcagcccccctttccaagcgggcggcgcgcgaggctgcggcgagg 
-540 cctgagccctgcgttcctgcgctgtgcgcgcccccaccccgcgttccaatctcaggcgct 
-480 ctttgtttctttctccgcgacttcagatctgagggattccttactctttcctcttcccgc 
-420 tcctttgcccgcgggtctccccgcctgaccgcagccccgagaccgccgcgcacctcctcc 
-240 cqqaaa~ccccc~gtcccagcccagcgctgaagtaacgggaccatgcccagtcccag 
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-60 tttcctaacggggttataaaaacagcgccctcggcggggtccagtcctctgccactctc -1 
0 ctccgaggtccccgcgccagagacgcagccgcgctcccaccacccacacccaccgcgccC 
tcgttcgcctcttctccgggagccagtccgcgccaccgccgccgcccaggccatcgccAc 
cctccgcagccATGTCCACCAGGTCCGTGTCCTCGTCCTCCTACCGCAGGATGTTCGGCG 
GCCCGGGCACCGCGAGCCGGCCGA 
Figure 17B: Nucleotide sequence of the vimentin promoter. Specific regulatory 
elements are indicated (underline). Coding sequence is indicated (capitals). 
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Figure 17C: HN12 cells were transfected with vimentin promoter fragments, which 
begin at +72 and extend to -261, -719, -749, and -757 as described in 'Materials and 
Methods'. 24h after transfection, cells were serum starved for 24h and then CAT activity 
was determined by ELISA assay. The relative expression ratio is defined as the 
expression level of vimentin to that of an internal standard, GFP. Values shown are 
meanskl SD. 
Figure 17D: Effects of EGF and TGF-P on vimentin promoter activity. HN12 cells were 
transfected with 757 CAT plasrnid. Serum was withdrawn for 24h, then cells were 
treated with the indicated growth factors for 24h after which CAT activity was 
determined by ELISA assay. The relative expression ratio is defined as the expression 
level of vimentin to that of an internal standard, GFP. Values shown are means+lSD. 
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Figure 17E: Effects of EGF and TGF-P on vimentin promoter activity. HN12 cells were 
transfected with 261 CAT plasmid. Serum was withdrawn for 24h, then cells were 
treated with the indicated growth factors for 24h after which CAT activity was 
determined by ELISA assay. The relative expression ratio is defined as the expression 
level of vimentin to that of an internal standard, GFP. Values shown are means+lSD. 
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Figure 17F: Effects of EGF and TGF-P on vimentin promoter activity. HN12 cells were 
transfected with 749 CAT plasmid. Serum was withdrawn for 24h, then cells were 
treated with the indicated growth factors for 24h after which CAT activity was 
determined by ELISA assay. The relative expression ratio is defined as the expression 
level of vimentin to that of an internal standard, GFP. Values shown are means+lSD. 
5. Discussion 
5.1 Aims of Current Study 
The aims of this study were to determine how vimentin expression differs in 
primary and metastatic HNSCC cells; to determine if vimentin expression is modulated 
by the invasion-inducing growth factors TGF-P and/or EGF; to determine if vimentin 
expression contributes to the invasive phenotype of metastatic HNSCC cells; and to 
determine what mechanisms regulate vimentin gene transcription in metastatic HNSCC. 
5.2 HNSCC Model System 
In order to develop a model system to study the nodal metastasis or oral squamous 
cell carcinoma, the HN4 cell line was generated from a primary carcinoma of the tongue 
and the HN12 cell line from a co-existing lymph node metastasis. Both of the cell lines 
were found to have undergone identical inactivation of CDKN2A and P.53 genes, which 
strongly suggests that the metastatic cells were the results of malignant progression of 
cells from the primary lesion (Yeudall et al., 1994; Yeudall et al., 1997) and that they 
were likely to have a similar genetic background. Previous studies have demonstrated 
that P53 (Burns et al., 1994; Koch et al., 1994) and CDKN2A (Yeudall et al., 1994) 
mutation found in the primary tumor are maintained during metastatic progression. HN4 
cells were unable to form tumors in immunodeficient mice and HN12 cells were highly 
tumorigenic in vivo, indicating that the HN12 cells are at a more advanced stage of tumor 
progression (Yeudall et al., 2005). 
5.3 Microarras Data 
A high throughput analytical method, high density microarray technology, was 
used to identify the genetic alterations that occur during metastatic progression or 
primary oral squamous cell carcinoma (Miyazaki et al., 2005). The gene set documented 
in this report, including ilimentin, overlap those identified from in vivo studies. which 
suggest that the model has relevance for the study of HNSCC metastasis (Miyazaki et al., 
2005). The high basal levels of vimentin present in the metastatic cells, consistent with 
their more mesenchymal appearance as well as the expression being elevated by both 
EGF and TGF-P served as the foundation for the present study. 
In addition, simultaneous exposure of both growth factors to HN12 cells resulted 
in a higher level of vimentin expression than that found with either EGF or TGF-P alone 
indicating some level of cooperatively between the EGF- and TGF-P-dependent signaling 
pathways to the upregulation of vimentin expression (Miyazaki et al., in press). Here, we 
investigate regulation of the vimentin promoter in the presence of EGF and TGF-P to 
determine distinct promoter elements acted upon by these signaling pathways. 
5.4 Vimentin as a Molecular Marker 
Different intermediate filament proteins serve as markers for the identification of 
normal, highly differentiated cells (Anguelov, 2000). Furthermore, intermediate filament 
proteins are relied upon to help diagnosis tumor types, for example, vimentin is being 
used as a marker for melanomas and keratin as a marker for adenocarcinomas (Anguelov, 
2000). Molecular markers for malignancy, such as vimentin, are expected to become 
reliable prognostic tools that will aid oncologists in fine-tuning their cancer management 
strategies (Anguelov, 2000). This molecular diagnosis would allow physicians to stage 
the patient's cancer more effectively and specifically tailor a treatment strategy that is 
clinically and cost effective (Anguelov, 2000). 
5.4.1 Upregulation of Vimentin in HN12 cells 
In this study, vimentin RNA was found to be more abundant in HN12 cells 
compared to HN4. Vimentin overexpression in HN12 cells was confirmed by western 
blot analysis, immunocytochemical staining, and immunofluorescence microscopy. 
Immunocytochemical staining showed strong vimentin ubiquitous staining in HN12 cells, 
whereas this was absent in HN4 cells and immunofluorescence microscopy revealed a 
dense network of vimentin filaments in the HN12 cells. These findings confirm that 
expression of vimentin is upregulated in cells at a later stage of tumor progression 
confirming the microarray findings. Concurrent with our results, other metastatic cell 
lines have also been reported an upregulation in expression of the intermediate filament, 
vimentin. 
Using an androgen-independent model of prostate cancer, among the 
differentially expressed genes between the two cells lines, LNCaP and CL1, vimentin 
was overexpressed 20-fold in the CLl  cells (Singh et al., 2003). The androgen-sensitive 
LNCaP prostate cancer cell line is less invasive than hormone-insensitive cell lines 
(Singh et al., 2003). CL1 is an aggressive hormone-insensitive LNCaP subline that was 
derived by continuous culture in hormone-depleted medium (Singh et al., 2003). 
Upregulation of vimentin expression was confirmed by northern and western blots and 
visualized by immunofluorescence microscopy (Singh et al., 2003). In addition, these 
data confirm the findings of previous studies in which the phenotypes of prostate cancer 
cell line have been examined and LNCaP cells showed low levels of vimentin expression 
in contrast to the ?igh expression seen in their more aggressive DU145 and PC3 
counterparts (Nagle et al., 1987; Mitchell et al., 2000). 
5.5 Vimentin Expression and Epithelial to Mesenchymal Transition 
A major problem in cancer management is metastasis, the ability of the primary 
tumor cells to migrate by the way of the blood or lymphatic vessels and to form tumors at 
distant sites. It has been reported that EMT facilitates the dissemination of single 
carcinoma cells from the sites of primary tumors and is involved in the dedifferentiation 
that is typical of metastatic carcinoma (Theiry, 2002). Originally, EMT was described in 
the morphogenic remodelings during embryonic development (Hay, 1995; Boyer et al., 
1999). The acquisition of mesenchymal features by epithelial cells induced migration 
during embryological processes (Savagner et al., 1994; Hay, 1995). 
Now, we have come to appreciate the contribution of this phenomenon to both 
pathological and normal processes where EMT can be diagnosed by the expression of 
vimentin and the loss of epithelial cell-adhesion molecules (Savagner et al., 1994; Hay, 
1995). EMT has been shown to occur in cultured mammary epithelial cells (Stoker et al., 
1987) in a bladder carcinoma cell line, NBT-11 (Boyer et al., 1989) and a prostate 
carcinoma cell line (Singh et al., 2003). In culture, the definition of EMT is limited to 
the escape of single cells from epithelial sheets, increased motility, and a modification of 
the differentiation so that the migrating cells no longer express epithelial characteristics, 
but require a mesenchymal phenotype (Boyer et al., 1989). 
Using the bladder cell line, NBT-11, a study showed the mesenchymal phenotype 
defined by the acquisition of vimentin, while the loss of the epithelial phenotype is 
defined by the decline in keratin expression, in which a single marker defines the 
phenotype (Petersen et al., 2001). It is this definition that has been adopted in the field of 
breast cancer research (Petersen et al., 2001). 
Thus, in a report studying EMT in human micrometastatic and primary breast 
carcinoma cells, findings showed that all micrometastatic cancer cell lines displayed loss 
of epithelial cytokeratins (CK8, CK18, and CK19) and ectopic expression of vimentin 
commonly present in mesenchymal cells (Willipinski-Stapelfeldt et al., 2005). 
Immunohistochernical analysis of breast cancer samples further showed that the loss of 
cytokertain and ectopic vimentin expression were significantly associated with a higher 
tumor grade and higher mitotic index. This study indicated that micrometastatic cancer 
cells exhibit marked changes in the expression of cytoskeletal proteins indicative of EMT 
and is associated with the aggressive behavior of breast cancer cells in vivo (Willipinski- 
Stapelfeldt et al., 2005), and is consistent with our observations in HNSCC cells. This 
increased expression of vimentin it the metastatic cell has been suggested as a critical 
marker to distinguish 'true con~plete EMT7 from cell scattering' or 'partial EMT' 
(Grunert et al., 2003). 
5.6 Vimentin Expression Suppressed in HN12 Cells 
In order to study the contribution of vimentin expression to the biological 
properties of HN12 cells, we used RNA interference (RNAi) technology to reduce 
vimentin levels. Colonies were screened for vimentin expression by qRT PCR, western 
blot analysi:,, and immunofluorescence, which showed a cytosolic distribution pattern of 
staining in the HN12-NTC clones and the absence of staining in the HNl2-shVim clones. 
HNl2-shVim clones show an efficient reduction compared to non-targeting controls and 
thus were suitable for investigating the contribution of vimentin expression to the 
biological phenotype of metastatic HN12 cells. 
5.7 Vimentin Expression and Biological Properties 
The ability of tumor cells to migrate and invade , which is interpreted clinically as 
tumor aggressiveness, has been associated with changes in intermediate filaments 
(Anguelov, 2000). The deregulation of intermediate filament gene expression in tumor 
cells results in an intermediate filament phenotype, which is conducive to a higher 
potential for invasion and migration (Anguelov, 2000). The observation that an altered 
intermediate filament phenotype is associated with the ability of tumor cells to invade 
adjacent tissues and organs and migrate in specific ways throughout the body could lead 
to new strategies for cancer management. 
5.7.1 Vimentin Expression is Important for the Biological Properties of HNSCC 
The presence of regional metastasis in patients with HNSCC is a common adverse 
event associated with poor prognosis and high mortality (Howell and Grandis, 2005). 
Squamous carcinoma cells tend to grow more rapidly andlor fail to die at a normal rate. 
In addition, these cells can also invade surrounding tissue and metastasize. 
In order to determine whether the mesenchymal cell marker, vimentin, contributes 
to the phenotype of HN12 cells, we first compared the proliferation rate in culture of 
HN12-shVim and HN12-NTC cells. HNl2-shVim clones exhibit a marked decrease in 
proliferation compared to the HN12-NTC cells, suggesting that vimentin contributes 
positively to cell growth. In addition, in vitro invasion through Matrigel and migration 
assays displayed markedly decrease in cells with lower expression of vimentin. These 
findings indicate a crucial role for vimentin in the proliferation and invasion of metastatic 
HN12 squamous carcinoma cells. 
In accord with our HNSCC results, a study comparing the phenotype and 
behavior of seven head and neck squamous cell carcinoma cell lines found that the 
presence of the intermediate filament, vimentin coincided with the loss of anchorage 
dependency and a malignant phenotype (Tomson et al., 1996). 
5.7.2 Vimentin Expression and Biological Properties of Other Cell Lineages 
After establishing that vimentin expression was only slightly detectable in LNCaP 
cells and highly expressed in the faster-growing, more aggressive CLI subline, the study 
mentioned previously (Section 5.4.2) assessed the contribution of vimentin to an invasive 
phenotype (Singh et al., 2003). This study found that experimentally reducing the 
expression of vimentin in the CLI cell line effectively abolished the invasive potential of 
CL1 in the in vitro Matrigel invasion assays (Singh et al., 2003). 
In addition, breast and cervical carcinoma models show the expression of 
vimentin and the loss of E-Cadherin, an epithelial cell marker, to be associated with high 
invasiv.- abilities (Gilles et al., 1997) Experiments conducted with a breast cancer cell 
line showed that transient down-regulation of vimentin in MDA-MB-231 cells led to a 
decrease in their migratory ability (Hendrix et al., 1997). The findings of another breast 
cancer study revealed adriamycin-resistant MCF-7 cells expressing vimentin with 
diminished keratin 19 expression to reduce desmosome and tight junction formation as 
determined by reduced immunodetection of their components desmoplakins I and I1 and 
zonula occludens (20)-1 (Sommers et al., 2002). Consistent with our data in HNSCC 
cells, these studies confirm vimentin's central role in the proliferation and 
motility/invasiveness of advanced stage tumor cells. 
5.8 Expression of the Vimentin Promoter in HN12 Cells 
How the vimentin gene is regulated is important for understanding the 
relationship between gene expression and tumor progression, and, based on our data 
presented above, could ultimately contribute to controlling the invasiveness of some 
tumors. For the most part, vimentin expression coincides with cellular growth and is cell 
cycle regulated (Franke et al, 1979; Rittling and Baserga, 1987). We used vimentin 
promoter fragments, which begin at +72 and extend to -261, -719, -749, and -757 
relative to the translational start site to investigate which transcription factor binding sites 
mediate upregulation of vimentin expression in HN12 cells. The current model of 
eukaryotic gene regulation suggests that many positive and negative acting factors 
control the expression of the vimentin promoter (Wieczorek et al., 2000). 
The 261CAT sequence containing the GC-box, PEA3 and NF-KB sites showed 
substantial activity under conditions of growth factor withdrawal. It has been reported 
that at least eight sequences, which match the GC-box consensus site were found within 
the vimentin promoter (Rittling and Baserga, 1987). However, findings show that of 
these multiple GC-boxes, expression of the vimentin promoter is dependent on GC-box1 
located at position -64 which binds Spl (Izmailova et al., 1999). Mutation of the GC- 
box1 to a nonfunctional sequence results in little reporter gene expression despite the 
addition of considerable upstream DNA demonstrating that this element is required for 
regulated gene expression (Izmailova et al., 1999). Here, our findings demonstrate that 
the transcriptional elements within 261CAT are important regulators for the activation of 
vimentin expression with evidence specifically pointing to GC-box and NF-KB sites. 
A recent article reveals that the activation of the transcription factor, NF-KB, 
occurs in many human tumors and studies have shown that NF-KB can promote cell 
proliferation and oncogenesis, possibly by protecting cells from apoptosis (Huber et al., ' 
2004). Little is known about whether NF-KB is involved in tumor progression including 
EMT, which is a central process governing both morphogenesis and carcinoma 
progression in multicellular organisms. However, in a combined in vitro/in vivo model of 
mammary carcinogenesis, NF-KB was found to be essential in both the induction and 
maintenance of EMT and for in vivo metastasis (Huber et al., 2004). 
The activity of the vimentin promoter was much reduced in cells transfected with 
the 719CAT plasmid, which contains two sites (PS and H4TF-1) that bind the ZBP-89 
repressor protein. ZBP-89 is a zinc-finger, Kruppel-like protein, which is thought to be 
ubiquitously expressed (Wu et al., 2004). ZBP-89 is a transcriptional repressor in the 
case of vimentin (Wieczorek et al., 2000), epithelial neutrophil-activating peptide-78 
(Keates et al., 2001), gastrin (Merchant et al., 1996), ornithine decarboxylase (Law et al., 
1998b), and bovine adrenodoxin (Law et al., 2000). However, for other genes such as 
p21 (Hasegawa et al., 1999), a lymphocyte-specific protein tyrosine kinase (lck) (Yamada 
et al., 2001), type 1 collagen (Hasegawa et al., 1997), and stromelysin (Ye et al., 1999), it 
appears to activate gene expression (Wu et al., 2004). Furthermore, it has been suggested 
that ZBP-89 is a negative regulator of cell growth as overexpression in two gastric tumor 
cell lines (GH4 and AGS) inhibited cellular proliferation and led to cell cycle arrest of 
GH4 cells in G1 (Remington et al., 1997). 
Exactly, how ZBP-89 can function both as an activator and as a repressor of gene I 
I 
expression is unknown. It has been proposed that, for some genes, ZBP-89 and Spl can I 
compete for binding to a GC-rich sequence (Law et al., 1998a). However, in the case of I 
the vimetin promoter, a separate PS element (at position -319 to -278) has been found, I 
which does not directly bind Spl (Wieczorek et al., 2000). Thus, in the vimentin gene, 
ZBP-89 and Spl (or Sp3) bind to separate DNA elements and interact with each other 
directly (Zhang et al., 2003). It has been proposed that this interaction accounts for the 
dependence of vimentin gene activity on a functional GC-box1 and its associated factors 
(Wieczorek et al., 2000). Evident by our results using 719CAT is the apparent 
interaction between ZBP-89 and PS and H4TF-1, transcriptional factors within the 
promoter to repress the expression of vimentin. 
Moderate restoration of activity was achieved with the addition of two AP 1 
binding sites in the promoter (749CAT). Previous studies have implicated the activator 
protein (API) transcription factors in tumor progression (Young et al., 1999). The APl 
family of basic, leucine-zipper (bZIP) proteins is composed of heterodimers of Jun (c- 
Jun, JunB, JunD), Fos (cFos, FosB, Fral and Fra2) or ATF (ATF-1, ATF-2)/CREB, or 
homodimers of JunIJun (Angel and Karin 1991; Rahmsdorf, 1996). Given the large 
number of interactive partners, it is evident that the AP1 family can mediate the 
expression of a wide variety of genes that could contribute to tumor progression (Wu et 
al., 2003). The tandem AP1 sites with the vimentin promoter have been shown to be 
important for the serum and TPA inducibility of the vimentin gene (Rittling et al., 1989), 
as well as expression in vimentin-positive breast cancer cell lines (Sommers et al., 1994). 
Here, the impacts of the AP1 sites on the vimentin promoter is evident not only with the 
data demonstrating the increase of vimentin expression with the 749CAT plasmid 
compared to 719CAT, but also the substantial decrease seen when the AP1 sites are 
mutated in the 747mCAT. 
It has been reported that, unlike many other proteins, c-Jun has the ability to 
activate vimentin gene expression both by the classical method of c-Jun binding as either 
a homodimer or heterodimer to its tandem APl sites as well as by an independent, 
synergistic interaction with Spl, thereby enhancing its ability to recruit transcription 
factors (Wu et al., 2003). In addition, it has been reported that cJun synergizes with Spl 
to enhance its subsequent binding to a GC-box element and only the leucine-zipper 
region of c-Jun is required for this (Wu et al., 2003). This dual mechanism of action 
could greatly affect levels of gene expression. 
Addition of the ASE site (757CAT) further increased promoter activity. 
Previously. it has been reported that the vimentin gene promoter contain an ASE site, 
which is unlike the usual enhancer element in that it requires the presence of the PS 
silencer element in cis to activate transcription fully (Stover and Zehner, 1992; Izmailova 
and Zehner, 1999). It has been reported that the upstream ASE antisilencer site binds 
Stat3 whereby its interaction with ZBP-89 can overcome repression and restore gene 
expression (?Vu et al., 2004). Therefore Stat3, a proven oncogene, can interact with a 
suggested growth suppressor, ZBP-89, to restore gene expression (Wu et al., 2004). 
Thus, the interplay between Stat3 and ZBP-89, which could contribute to the activation 
of vimentin gene expression as occurs in EMT (Gilles and Thompson, 1996) and is 
crucial for controlling cellular growth by direct effects on gene expression. 
Stats are a family of transcriptional activators, which play a central role in 
signaling pathways involving cytokines, growth factors, or peptide hormones (Ihle, 1996; 
Darnell, 1997; Horvath, 2000; Levy and Darnell, 2002). Activated receptors are protein- 
kinases of the JAK family, which phosphorylate Stats. Phosphorylated Stats form dimers 
via their SH2 domains and rapidly translocate to the nucleus where they bind regulatory 
DNA elements of target genes involved in cell proliferation, differentiation, apoptosis, 
and development (Wu et al., 2004). 
Stat3 is constitutively active in many tumors such as lymphomas, leukemia, 
multiple myeloma, brain, breast, lung, head and neck, and prostate cancers (Bowman et 
al., 2000), and the constitutively active form of Stat3 can mediate cellular transformation 
(Bromberg et al., 1999). In addition, vimentin has been shown to be highly expressed in 
these tumors (Busserrrtkers et al., 1992; Hsieh et al., 1995; Zajchowski et al., 2001). 
Thus, a correlation between activated Stat3 and vimentin gene expression is indicated, 
which coincides with the results of this present study. 
In conclusion, the data suggest that basal activity of the vimentin promoter in 
HN12 cells is mediated through ASE and API sites, as well as one or more of the GC 
box, PEA3 and NF-lcB sites. Furthermore, the data indicate that ZBP-89 repressor 
activity is high in these cells. 
5.9 EGF and TGF-6 and Vimentin Expression 
Epidermal growth factor (EGF) and transforming growth factor P (TGF-P) are 
thought to contribute to tumor metastasis through a number of mechanisms, including 
enhanced cell migration and EMT, and have been demonstrated to enhance migration and 
invasion of HN12 cells (Yeudall et al., 2005; Miyazaki et al., in press). Vimentin RNA 
was increased in TGF-P treated cells over basal expression levels, as well as with the 
addition of EGF. In addition, a synergistic increase was evident when cells were treated 
with a combination of TGF-P and EGF, suggesting that both growth factors play a role in 
EMT in this system. In addition, western blot analysis demonstrated increased levels of 
vimentin protein were detected in TGF-P and EGF-treated HN12 cells, concomitant with 
the previously observed rise in vimentin RNA and immunocytochemical staining, HN12 
cells displayed an ubiquitous distribution pattern of vimentin throughout the cell, which 
was further enhanced with the addition of EGF and TGF-P. 
5.10 EGF and TGF-B and the Virnentin Promoter 
Next, we examined vimentin promoter activity in the presence of EGF and TGF-P 
to determine the binding elements responsible for the increased vimentin expression 
observed by qRT-PCR, western blot analysis, irnrnunocytochemistry, and 
immunofluorescence. Using the 757CAT sequence, we found that treatment of cells with 
either EGF or TGF-0 stimulated promoter activity above that observed under conditions 
of serum withdrawal, while the presence of both growth factors further elevated CAT 
activity. In contrast, CAT activity in cells transfected with the 261CAT sequences 
(containing the GC box, PEA3 and NFKB sites) was maximal in the presence of EGF, 
which stimulated promoter activity. However, in cells transfected with the 749CAT 
plasmid, TGF-P produced an increase in promoter activity over basal levels, whereas 
EGF had little effect. 
Taken together, the data suggest that EGF-dependent pathways target binding 
elements in the proximal vimentin promoter, while TGF-P is likely to act in an AP1- 
dependent manner. Furthermore, both growth factors appear to synergize by stimulating 
promoter activation through the ASE site, suggesting involvement of Stat-dependent 
pathways in regulation of vimentin expression in HN12 cells. Here, our findings 
demonstrate that the induction of vimentin expression with the addition of growth factors, 
EGF and TGF-P occurs at the transcriptional level of the promoter targeting specific 
transcriptional sites. 
5 11 TGF-8 and Tumorigenesis 
TGF-P is a multipotent cytokine that regulates a variety of cellular activities, such 
as cell proliferation, differentiation, and extracellular matrix (ECM) formation (Liberati 
et al., 1999). TGF- P plays a complex role in tumorigenesis since it has both tumor 
suppressor and oncogenic activities (Akhurst and Derynck, 2001; Derynck et al., 2001; 
Wakefield and Roberts, 2002). During the early stages of tumorigenesis, TGF- P, acts as 
a tumor suppressor. It is suggested to be predominantly through its ability to induce 
growth factor arrest and apoptosis in epithelial cells for which the majority of human 
cancers derive (Nicolas and Hill, 2003). It is at the late stages when the pro-oncogenic 
activities of TGF- P dominate. TGF- P acts directly on the tumor cells to induce EMT, 
and to increase motility, invasiveness and metastasis, and on the surrounding stroma to 
suppress immune surveillance and increase angiogenesis (Akhurst and Derynck, 2001; 
Derynck et al., 2001 ; Wakefield and Roberts, 2002). 
TGF-P profoundly influences the differentiation of many cell types of 
mesechymal origin, including preadipocytes (Ignotz and Masague, 1985; Choy et al., 
2000) osteoblasts (Centrella et al., 1994) and myoblasts (Olson, 1992). The identification 
of genes transcriptionally regulated by TGF-P and the elucidation of the molecular 
mechanisms responsible for this transcriptional regulalion will help define how TGF-P 
exerts its cellular effects and its role in resulting physiological processes (Liberati et al., 
1999). 
Interestingly, research studies have shown that it is the association of the Smad 
complexes with transcription factors and transcriptional co-activators/co-repressors in the 
nucleus that further regulate transcriptional control by TGF-P (Davies et al., 2005). The 
receptor-associated Smads (R-Smads) interact directly with, and are phosphorylated by, 
activated type I receptors of the TGF-P superfamily (Verrecchia et al., 2001). 
5.12 TGF-D and AP1 Binding Sites 
Numerous studies have characterized the differential expression of specific genes 
in response to TGF-P, revealing a common link in the ability of TGF-P to regulate many 
of these genes through the functions of the AP-1 family of transcription factors (Liberati 
et al, 1999). The ability of TGF-P to induce the expression of several genes, including 
PAI- 1, clusterin, monocyte chemoattractant protein- 1 (JEIMCP- I), type I collagen, and 
TGF-P itself depends on specific APl DNA-binding sites in the promoter regions of 
these genes (Keeton et al., 1991 ; Jin and Howe, 1997; Armendaruz-Borunda et al., 1994; 
Kim et al., 1990; Takeshita et al., 1995; Mauviel et al., 1996). I t  has also been shown 
that expression of many APl proteins themselves is induced as an early response to TGF- 
0 in a cell type-specific manner (Beauchamp et al., 1996; Blatti et al., 1992; Pertovaara et 
al., 1989; Wong et al., 1999). These studies demonstrate a link between TGF-P signaling 
and API in TGF-P regulated expression of various genes (Liberati et al., 1999). 
Interestingly, components of the AP1 transcriptional complex were recognized early as 
transcriptional targets of TGF-P signaling before the mechanisms of TGF-p transduction 
were known (Pertovaara et al., 1989; Mauviel et al., 1998; Kim et al., 1990) 
5.13 TGF-13 Induction via Smad Dependent and Independent Pathways 
k has becn suggested that several genes, such as those encoding the plasminogen 
activator inhibitor-1 (PAI-I), the a 2  chain of type I collagen (COLlA2), or the interstitial 
collagnease (MMP-l), in which TGF-0 responsiveness was originally described as AP-1 
dependent (Keeton et al., 1991; Chung et al., 1996; Mauviel et al., 1996) can also be 
regulated by Smads, via either Smad-specific cis elements. It is known that Smad3 
activation occurs in response to TGF-p, in which Smad3DNA interaction is detectable as 
early as 10 minutes after TGF-P addition (Vindevoghel et al., 1998a). Recent findings 
have demonstrated transcriptional responses depend on the structure of the target 
promoter, whether they contain APl or Smad specific cis-elements (Verrecchia et al., 
2001). 
It is now recognized that TGF-PI can activate mitogen-activated protein kinases 
(MAPKs) (Hartsough and Mulder, 1995; Yamaguchi et al., 1995; Atfi et al., 1997; 
Bhowmick et al., 2001b). The APl transcriptional complex is a primary target of a 
number of MAPK pathways and it has been shown that APl components can interact 
directly with Smad3 (Zhang et al., 1998, Peron et al., 2001; Verrechia et al., 2001). This 
suggests that API may be central to crosstalk between Smad and MAPK pathways 
(Davies et al., 2005). 
There is convincing evidence for the involvement of MAPK signaling in TGF-PI- 
induced EMT (Ellenrieder et al., 2001; Zavadil et al., 2001; Bakin et al, 2002). A recent 
study showed that TGF-pl-induced EMT involves Smad-dependent pathways (Davies et 
al., 2005), which is in agreement with the limited number of studies using cells of human 
origin (Ellenrieder et al., 2001; T i ~ n  et al., 2003). MAPKs function to enhance Smad 
213-dependent transcription TGF-p 1 -induced EMT (Davies et al., 2005). In conclusion, 
MAPK and Smads pathways, together with the AP-1 complex mediate TGF-p 1-induced 
EMT (Davies et al., 2005). 
These research findings confirm our results, in which cells transfected with the 
749CAT plasmid, TGF-P produced a substantial increase in promoter activity over basal 
levels. This upregulation of the 749CAT vimentin promoter can be explained through 
TGF-P interaction with the promoter tandem APl sites as there are a number of research 
findings that provide strong evidence to support the role of Ap-1 in TGF-pl-induced 
EMT. 
Interestingly, research studies also show that the transcriptional factor NF-KB 
functionally cooperates with Smad3 as well as the transcriptional factor protein, Spl,  
which is found to functionally cooperate with Smad 21314 (Miyazono et al., 2001) These 
research findings can be used to explain the upregulation of vimentin expression with the 
addition of TGF-P to the 261CAT plasmid since both Smad 2 and 3 are activated by the 
growth factor TGF-P. 
5.14 EGFR Induction 
The precise mechanisms by which growth factor-induced cell surface signals are 
transmitted to the nucleus and ultimately result in cell division are partially understood. 
In the response to ligands, EGFR dimerizes and becomes phosphorylated on multiple 
tyrosine residues. These phosphotyrosines, in turn, allow the activated receptor* 
associate with other signaling proteins. Several EGFR signaling intermediates have been 
described including ras/MAP kinase, PI-3-kinase, and PLCy. 
5.15 EGF and spl bind in^ Protein 
Despite the proven ability of spl to regulate the transcriptional activity of a 
variety of genes involved in cell differentiation and proliferation (Merchant et al., 1995, 
Li et al., 1995), little is known about its role in tumor growth and progression. High 
levels of spl have been reported in gastric carcinomas (Kitadai et al., 1992) and a 
coordinate overexpression of spl and lamin-yl was found in human hepatocellular 
carcinomas (Lietard et al., 1997). 
In a study using breast cancer models, western blot analysis with anti-Spl 
antibody on nuclear extracts from seven malignant specimens and three breast lesions 
conformed the presence of varying nuclear levels of spl proteins in the malignant tumors 
and the absence of a detectable signal in benign breast lesions (Zannettii et al., 2000). 
Promoter assays were studied and the binding data reflect Spl protein relative to the 
levels assessed by western blot analysis of the same samples (Zannettii et al., 2000). 
In addition , it has been previously shown for other genes, such as, gastrin 
(Porchet et al., 1999) or apolipoprotein A-I (Zheng et al., 2001), that spl may participate 
to EGF-mediated up-regulation of the target gene. Using a lung cancer cell line, 
researchers were able to show in MUC2 and MUCSAC, two target genes of EGFR 
ligands in lung cancer. cells, that spl not only transactivated MUC2 and MlJC5AC 
transcription but also participates in their up-regulation by EGF and TGF-a (Perrais et 
al., 2002). 
These studies confirm the substantial activation of 261CAT by EGF, indicating 
that EGF targets the spl transcriptional binding protein within the vimentin promoter. 
Interestingly, further studies might investigate the amount of spl protein in metastatic 
HN12 cells to determine that not only is spl activated by EGF signaling pathway, but 
there might also be an increased present amount of spl protein in the metastatic cell 
similar to the breast cancer mentioned previously. In conclusion, these studies help 
define new therapeutic strategies in carcinomas in which one may want to efficiently and 
selectively inhibit EGFR-signaling pathway to reduce or prevent metastasis. 
5.16 Stat3 Protein and Metastasis 
It has been shown that the Stat3 protein plays an important role in the growth and 
survival of breast cancers in culture and in vivo (Gracia et al., 2001; Zajchowski et al., 
2001). Maximal Stat3 activation is thought to result from the cooperation of different 
growth factors receptors, cytokine receptors, and nonreceptor tyrosine kinases (Wu et al., 
2004). Thus, constitutive activation of Stat3 is more predominant in highly aggressive, 
metastatic breast cancers, and inhibiting Stat3 activation can block the malignant 
progression of breast tumors (Bowman et al., 2000; Gracia et al., 2001). Established 
breast cancer cell lines demonstrate constitutively active Stat3 homodimers (Sartor et al., 
1997). 
EGF has been shown to be capable of activating Stats 1 and 3 in EGFR- 
overexpressing cells (Zhong et al., 1994; Leaman et al., 1996; Chin et al., 1996; 
Nakamura et al., 1996), Stat activation in these cells has not been linked to proliferation 
or transformation. However, recent studies show that Src-induced transformation of 
fibroblasts results in Stat3-mediated gene expression (Turkson et al., 1998) and that Stat3 
is constitutively activated in breast carcinoma cell lines but not in normal breast epithelial 
cells (Gracia et al., 1997). The results presented in these studies are the first 
demonstration of growth inhibition after selective downmodulation of a Stat protein in 
EGFR-overexpressiong cells. 
These research findings confer with our results in which the EGF induced 
activation of the 757CAT vimentin promoter, which contains the ASE transcriptional site 
that is activated by the transcriptional protein, Stat3. In addition, 757CAT also displayed 
induction with the addition of growth factor, TGF-P. 
It has been proposed in other cell models the formation of a complex between 
Stat3 and Smadl indicating that these two binding motifs may physically interact via an 
adaptor molecule. The CREB-binding protein (CBP)/p300 family of transcriptional 
coactivators interact with various transcription factors, such as, APl, Myb, and nuclear 
receptors altering there activity (Kamei et al., 1998). Interestingly, Smadl, 2, 3, and 4 
associate with CBPlp300 family members (Nishihara et al., 1998; Janknecht et al., 1998). 
This study showed the formation of a complex between Stat3 and Smadl, bridged by 
p300, is involved in the cooperative signaling of LIF and BMP2 and the subsequent 
induction of astrocytes from neural progenitors (Nakashima et al., 1999). In conclusion, 
the transcriptiocnl cuactivator p300 physically interacts with Stat3 and Smadl, in which 
the formation of a complex between Stat3 and Smadl, bridgedby p300, is involved in the 
cooperative signaling of the pathway (Nakashima et al., 1999). 
With Smadl being a downstream target of TGF-P and CBPlp300 family members 
also associating with Smad2 and 3 provides strong evidence for the further increase in 
induction of the 757CAT plasmid with the addition of TGF-P compared to EGF 
stimulation alone. Furthermore, this concept provides increasing evidence for the 
synergistic effect found with the addition of both growth factors confirming Stat3 as the 
target for induction by both EGF and TGF-P. 
5.17 Conclusion 
In conclusion, HNSCC remains the sixth most common malignancy worldwide 
(Parkin et al., 1999; Landis et al., 1999). While primary lesion undergo hematogenous 
spread only rarely, they are locally aggressive, and frequently metastasize to local and 
regional lymph nodes, with lethal consequences (Yeudall et al., 2005). Therefore, it is 
the prevention and early detection that are of great importance to reduce the incidence of, 
and consequent morbidity from, HNSCC (Yeudall et al., 2005). One of the major goals 
to combat this disease involves the ability to prevent invasion and regional metastasis of 
the primary lesions. This requires a detailed understanding of the basic cellular biology 
and biochemistry of invasion and metastasis in this cell system (Yeudall et ul., 2005). 
With our findings, it can be suggested that particular transcription factors and the 
signaling pathways involved in their activation should receive attention as potential 
targets for the developments of novel anti-metastatic cancer treatments. .Fi.~ture studies 
involve using a CHIP assay to confirm the findings of the transcriptional data. As well as 
further evaluating our preliminary finding, which demonstrate a decrease of cytokertain 
in the metastatic, HN12 cell line. 
6. Future Experiments 
6.1 Dcw_nregulation of Cvtokeratirr in 1-IN12 cells 
Whereas vimentin is overexpressed in metastatic HN12 cells, an epithelial 
specific intermediate filament, cytokeratin, is downregulated. Here, we show that HN12 
cells demonstrate a downregulation of cytokeratin 13, 14, and 15 by western blot analysis 
of total cellular protein lysates. After 48h of serum starvation, total cell protein extracts 
were prepared as described in 'Materials and Methods' and analyzed for cytokeratin 
expression (top panels). Levels of !3-actin were determined as a loading control (lower 
panel). Anti-cytokeratin 13, 14, and 15 monoclonal antibodies were used (Waseem et al., 
1998; Waseem et al., 1999). 
Whereas each cytokeratin was readily detectable in HN4 cell lysates, no signal 
was obtained in HN12 lysates with cytokeratins 13 and 15 and diminished signal with 
cytokeratin 14. Furthermore, increased cytokeratin 13, 14, and 15 expression was 
detectable by western blot analysis in two HN12-shVim clones compared to the parental 
HN12 cell line and HN12-NTC clones. These data indicate that cytokeratin 13, 14, and 
15 expression is downregulated at a later stage of tumor progression. 
Watson, J. D. and F. H. Crick (1953). "The structure of DNA." Cold Spring Harb Symp 
Quant Biol 18: 123-3 1. 
Franke, W. W., E. Schmid, et al. (1979). "Widespread occurrence of intermediate-sized 
filaments of the vimentin-type in cultured cells from diverse vertebrates." Exp Cell Res 
123(1): 25-46. 
Ignotz, R. A. and J. Massague (1985). "Type beta transforming growth factor controls the 
.adipoqenic differentiation of 3T3 fibroblasts." Proc Natl Acad Sci U S A 82(2,4): 8530-4. 
Nagle, R. B., F. R. Ahmann, et al. (1987). "Cytokeratin characterization of human 
prostatic carcinoma and its derived cell lines." Cancer Res 47(1): 28 1-6. 
Rittling, S. R. and R. Baserga (1987). "Functional analysis and growth factor regulation 
of the human vimentin promoter." Mol Cell Biol7(11): 3908-15. 
Stoker, M. and E. Gherardi (1987). "Factors affecting epithelial interactions." Ciba Found 
Symp 125: 217-39. 
Boyer, B., G. C. Tucker, et al. (1989). "Rearrangements of desmosomal and cytoskeletal 
proteins during the transition from epithelial to fibroblastoid organization in cultured rat 
bladder carcinoma cells." J Cell Biol 109(4 Pt 1): 1495-509. 
Olson, E. N. and Y. G. Capetanaki (1989). "Developmental regulation of intermediate 
filament and actin rnRNAs during myogenesis is disrupted by oncogenic ras genes." 
Oncogene 4(7): 907-13. 
Pertovaara, L., L. Sistonen, et al. (1989). "Enhanced jun gene expression is an early 
genomic response to transforming growth factor beta stimulation." Mol Cell Biol9(3): 
1255-62. 
Rittling, S. R., L. Coutinho, et al. (1989). "AP-lljun binding sites mediate serum 
inducibility of the human vimentin promoter." Nucleic Acids Res 17(4): 1619-33. 
Kim, S. J., P. Angel, et al. (1990). "Autoinduction of transforming growth factor beta 1 is 
mediated by the AP-1 complex." Mol Cell Biol lO(4): 1492-7. 
Steinert, P. M. and R. K. Liem (1990). "Intermediate filament dynamics." Cell 60(4): 
52 1-3. 
Angel, P. and M. Karin (1991). "The role of Jun, Fos and the AP-1 complex in cell- 
proliferation and transformation." Biochim Biophys Acta 1072(2-3): 129-57. 
Keeton, M. R., S. A. Curriden, et al. (1991). "Identification of regulatory sequences in the 
type 1 plasminogen activator inhibitor gene responsive to transforming growth factor 
beta." J Biol Chem 266(34): 23048-52. 
Blatti, S. P. and R. E. Scott (1992). "Stable induction of c-jun mRNA expression in 
normal human keratinocytes by agents that induce predifferentiation growth arrest." Cell 
Growth Differ 3(7): 429-34. 
Bussemakers, M. J., G. W. Verhaegh, et al. (1992). "Differential expression of vinientin 
in rat prostatic tumors." Biochem Biophys Res Commun 182(3): 1254-9. 
Daopin, S., K. A. Piez, et al. (1992). "Crystal structure of transforming growth factor-beta 
2: an unusual fold for the superfamily." Science 257(5068): 369-73. 
Kitadai, Y., W. Yasui, et al. (1992). "The level of a transcription factor Spl is correlated 
with the expression of EGF receptor in human gastric carcinomas." Biochem Biophys 
Res Commun 189(3): 1342-8. 
Ogata, Y., J. J. Enghild, et al. (1992). "Matrix metalloproteinase 3 (stromelysin) activates 
the precursor for the human matrix metalloproteinase 9." J Biol Chem 267(6): 3581-4. 
Schlunegger, M. P. and M. G. Grutter (1992). "An unusual feature revealed by the crystal 
structure at 2.2 A resolution of human transforming growth factor-beta 2." Nature 
358(6385): 430-4. 
Stover, D. M. and Z. E. Zehner (1992). "Identification of a cis-acting DNA antisilencer 
element which modulates vimentin gene expression." Mol Cell Biol 12(5): 2230-40. 
Archer, S. J., A. Bax, et al. (1993). "Transforming growth factor beta 1: secondary 
structure as determined by heteronuclear magnetic resonance spectroscopy." 
Biochemistry 32(4): 1 164-7 1. 
Khazaie, K., V. Schirrmacher, et al. (1993). "EGF receptor in neoplasia and metastasis." 
Cancer Metastasis Rev 12(3-4): 255-74. 
Lilienbaum, A. and D. Paulin (1993). "Activation of the human vimentin gene by the Tax 
human T-cell leukemia virus. I. Mechanisms of regulation by the NF-kappa B 
transcription factor." J Biol Chem 268(3): 2180-8. 
Salvetti, A., A. Lilienbaum, et al. (1993). "Identification of a negative element in the 
human vimentin promoter: modulation by the human T-cell leukemia virus type I Tax 
protein." Mol Cell Biol 13(1): 89-97. 
Burns, J. E., R. McFarlane, et al. (1994). "Maintenance of identical p53 mutations 
throughout progression of squamous cell carcinomas of the tongue." Eur J Cancer B Oral 
Oncol 30B(5): 335-7. 
Burns, J. E., L. J. Clark, et al. (1994). "The p53 status of cultured human premalignant 
oral keratinocytes." Br J Cancer 70(4): 591-5. 
Centrella, M., M. C. Horowitz, et al. (1994). "Transforming growth factor-beta gene 
family members and bone." Endocr Rev 15(1): 27-39. 
Koch, W. M., J. 0 .  Boyle, et al. (1994). "p53 gene mutations as markers of tumor spread 
in synchronous oral cancers." Arch Otolaryngol Head Neck Surg 120(9): 943-7. 
Miettinen, P. J., R. Ebner, et al. (1994). "TGF-beta induced transdifferentiation of 
mammary epithelial cells to mesenchymal cells: involvement of type I receptors." J Cell 
Biol 127(6 Pt 2): 2021-36. 
Pertovaara, L., A. Kaipainen, et al. (1994). "Vascular endothelial growth factor is induced 
in response to transforming growth factor-beta in fibroblastic and epithelial cells." J Biol 
Chem 269(9): 6271-4. 
Savagner, P., B. Boyer, et al. (1994). "Modulations of the epithelial phenotype during 
embryogenesis and cancer progression." Cancer Treat Res 7 1 : 229-49. 
Sommers, C. L., S. W. Byers, et al. (1994). "Differentiation state and invasiveness of 
human breast cancer cell lines." Breast Cancer Res Treat 31(2-3): 325-35. 
Yeudall, W. A., R. Y. Crawford, et al. (1994). "MTSllCDK4I is altered in cell lines 
derived from primary and metastatic oral squamous cell carcinoma." Carcinogenesis 
15(12): 2683-6. 
Zhong, Z., Z. Wen, et al. (1994). "Stat3 and Stat4: members of the family of signal 
transducers and activators of transcription." Proc Natl Acad Sci U S A 91(11): 4806-10. 
Zhong, Z., Z. Wen, et al. (1994). "Stat3: a STAT family member activated by tyrosine 
phosphorylation in response to epidermal growth factor and interleukin-6." Science 
264(5 155): 95-8. 
Guarino, M. and F. Giordano (1995). "Experimental induction of epithelial-mesenchymal 
interconversions." Exp Toxic01 Path01 47(5): 325-34. 
Hartsough, M. T. and K. M. Mulder (1995). "Transforming growth factor beta activation 
of p44mapk in proliferating cultures of epithelial cells." J Biol Chem 270(13): 71 17-24. 
Hay, E. D. and A. Zuk (1995). "Transformations between epithelium and mesenchyme: 
normal, pathological, and experimentally induced." Am J Kidney Dis 26(4): 678-90. 
Hsieh, T. C., W. Xu, et al. (1995). "Growth regulation and cellular changes during 
differentiation of human prostatic cancer LNCaP cells as induced by T lymphocyte- 
conditioned medium." Exp Cell Res 21 8(1): 137-43. 
Li, B. Q., M. H. Wang, et al. (1995). "Macrophage-stimulating protein activates Ras by 
both activation and translocation of SOS nucleotide exchange factor." Biochem Biophys 
Res Commun 216(1): 110-8. 
Merchant, J. L., A. Shiotani, et al. (1995). "Epidermal growth factor stimulation of the 
human gastrin promoter requires Spl." J Biol Chem 270(11): 6314-9. 
Steller, H. (1995). "Mechanisms and genes of cellular suicide." Science 267(1445). 
Takeshita, A., Y. Chen, et al. (1995). "TGF-beta induces expression of monocyte 
chemoattractant JEImonocyte chemoattractant protein 1 via transcriptional factor AP-I 
induced by protein kinase in osteoblastic cells." J Irnmunol 155(1): 419-26. 
Yamaguchi, K., K. Shirakabe, et al. (1995). "Identification of a member of the MAPKKK 
family as a potential mediator of TGF-beta signal transduction." Science 270(5244): 
2008-1 1. 
Birchmeier, C., W. Birchmeier, et al. (1996). "Epithelial-mesenchymal transitions in 
cancer progression." Acta Anat (Basel) 156(3): 2 17-26. 
Chen, J. H., C. Vercamer, et al. (-1996). "PEA3 transactivates vimentin promoter in 
mammary epithelial and tumor cells." Oncogene 13(8): 1667-75. 
Chin, Y. E., M. Kitagawa, et al. (1996). "Cell growth arrest and induction of cyclin- 
dependent kinase inhibitor p2 1 WAFlICIPl mediated by STAT1 ." Science 272(5262): 
7 19-22. 
Chung, K. Y., A. Agarwal, et al. (1996). "An AP-1 binding sequence is essential for 
regulation of the human alpha2(I) collagen (COLlA2) promoter activity by transforming 
growth factor-beta." J Biol Chem 27 l(6): 3272-8. 
Cui, W., D. J. Fowlis, et al. (1996). "TGFbetal inhibits the formation of benign skin 
tumors, but enhances progression to invasive spindle carcinomas in transgenic mice." 
Cell 86(4): 53 1-42. 
Gilles, C., M. Polette, et al. (1996). "Vimentin expression in cervical carcinomas: 
association with invasive and migratory potential." J Path01 180(2): 175-80. 
Hanafusa, J. M. B. a. H. (1996). Proto-oncogenes in Normal and Neoplastic Cells. 
Hanahan, R. A. W. a. D. (1996). The Molecular Pathogenesis of Cancer. 
Ihle, J. N. (1996). "STATs: signal transducers and activators of transcription." Cell 84(3): 
33 1-4. 
Thk, J. N (1996). "STATs aid MAPKs: obligate or opportunistic partners in signaling." 
Bioessays 18(2): 95-8. 
Kitagawa, K., A. Murata, et al. (1996). "Epithelial-mesenchymal transformation of a 
newly established cell line from ovarian adenosarcoma by transforming growth factor- 
betal." Int J Cancer 66(1): 91-7. 
Leaman, D. W., S. Pisharody, et al. (1996). "Roles of JAKs in activation of STATs and 
stimulation of c-fos gene expression by epidermal growth factor." Mol Cell Biol 16(1): 
369-75. 
Livingston, J. F. L. a. D. M. (1996). The Tumor Suppressor Genes and Their Mechanisms 
of Action. 
Lowy, D. R. (1996). The Causes of Cancer. 
Martin, G. S. (1996). Normal Cells and Cancer Cells. 
Mauviel, A., K. Korang, et al. (1996). "Identification of a bimodal regulatory element 
encompassing a canonical AP-1 binding site in the proximal promoter region of the 
human decorin gene." J Biol Chem 271(40): 24824-9. 
Merchant, J. L., G. R. Iyer, et al. (1996). "ZBP-89, a Kruppel-like zinc finger protein, 
inhibits epidermal growth factor induction of the gastrin promoter." Mol Cell Biol 
16(12): 6644-53. 
Oft, M., J. Peli, et al. (1996). "TGF-beta1 and Ha-Ras collaborate in modulating the 
phenotypic plasticity and invasiveness of epithelial tumor cells." Genes Dev lO(19): 
2462-77. 
Pawson, T. (1 996). The Biochemical Mechanisms of Oncogene Action. 
Rahmsdorf, H. J. (1996). "Jun: transcription factor and oncoprotein." J Mol Med 74(12): 
725-47. 
Ruiz, P. and U. Gunthert (1 996). "The cellular basis of metastasis." World J Urol 14(3): 
141-50. 
Tomson, A. M., J. Scholma, et al. (1996). "Adhesion properties, intermediate filaments 
and malignant behaviour of head and neck squamous cell carcinoma cells in vitro." Clin 
Exp Metastasis 14(6): 501 -1 1. 
Atfi, A., M. Buisine, et al. (1997). "Induction of apoptosis by DPC4, a transcriptional 
factor regulated by transformjng 5rowth factor-beta through stress-activated protein 
kinaselc-Jun N-terminal kinase (SAPWJNK) signaling pathway." J Biol Chem 272(40): 
2473 1-4. 
Darnell, J. E., Jr. (1997). "STATs and gene regulation." Science 277(5332): 1630-5. 
Gilles, C., M. Polette, et al. (1997). "Expression of c-ets-1 mRNA is associated with an 
invasive, EMT-derived phenotype in breast carcinoma cell lines." Clin Exp Metastasis 
15(5): 5 19-26. 
Hendrix, M. J., E. A. Seftor, et al. (1997). "Experimental co-expression of vimentin and 
keratin intermediate filaments in human breast cancer cells results in phenotypic 
interconversion and increased invasive behavior." Am J Pathol 150(2): 483-95. 
Jin, G. and P. H. Howe (1997). "Regulation of clusterin gene expression by transforming 
growth factor beta." J Biol Chem 272(42): 26620-6. 
Knauper, V., S. Cowell, et al. (1997). "The role of the C-terminal domain of human 
collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and 
tissue inhibitor of metalloproteinase interaction." J Biol Chem 272(12): 7608-16. 
Lietard, J., 0. Musso, et al. (1 997). "Sp 1 -mediated transactivation of LamC 1 promoter 
and coordinated expression of laminin-gamma1 and Spl in human hepatocellular 
carcinomas." Am J Pathol 15 l(6): 1663-72. 
Lochter, A., S. Galosy, et al. (1997). "Matrix metalloproteinase stromelysin-1 triggers a 
cascade of molecular alterations that leads to stable epithelial-to-mesenchymal 
conversion and a premalignant phenotype in mammary epithelial cells." J Cell Biol 
139(7): 186 1-72. 
Remington, M. C., S. A. Tarle, et al. (1997). "ZBP-89, a Kruppel-type zinc finger protein, 
inhibits cell proliferation." Biochem Biophys Res Commun 237(2): 230-4. 
Sartor, C. I., M. L. Dziubinski, et al. (1997). "Role of epidermal growth factor receptor 
and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer 
cells." Cancer Res 57(5): 978-87. 
Yeudall, W. A., J. Jakus, et al. (1997). "Functional characterization of p53 molecules 
expressed in human squamous cell carcinomas of the head and neck." Mol Carcinog 
18(2): 89-96. 
Dhooge, I. J., M. De Vos, et al. (1998). "Multiple primary malignant tumors in patients 
with head and neck cancer: results of a prospective study and future perspectives." 
Laryngoscope 108(2): 250-6. 
Grandis, J. R., Q. Zeng, et al. (1998). "Normalization of EGFR mRNA levels following 
restoration of wild-type p53 in a head and neck squamous cell carcinoma cell line." Int J 
Oncol 13(2): 375-8. 
Grandis, J. R., S. D. Drenning, et al. (1998). "Requirement of Stat3 but not Stat1 
activation for epidermal growth factor receptor- mediated cell growth In vitro." J Clin 
Invest 102(7): 1385-92. 
Janknecht, R., N. J. Wells, et al. (1998). "TGF-beta-stimulated cooperation of smad 
proteins with the coactivators CBPIp300." Genes Dev 12(14): 21 14-9. 
Janrney, P. A., J. V. Shah, et al. (1998). "Viscoelasticity of intermediate filament 
networks." Subcell Biochem 3 1: 381-97. 
Kornberg, L. J. (1998). "Focal adhesion kinase and its potential involvement in tumor 
invasion and metastasis." Head Neck 20(8): 745-52. 
Kornberg, L. J. (1998). "Focal adhesion kinase expression in oral cancers." Head Neck 
20(7): 634-9. 
Law, G. L., H. Itoh, et al. (1998). "Transcription factor ZBP-89 regulates the activity of 
the ornithine decarboxylase promoter." J Biol Chem 273(32): 19955-64. 
Nakashima, M., T. Toyono, et al. (1998). "Transforming growth factor-beta superfamily 
members expressed in rat incisor pulp." Arch Oral Biol43(9): 745-5 1. 
Nishihara, A., J. I. Hanai, et al. (1998). "Role of p300, a transcriptional coactivator, in 
signalling of TGF-beta." Genes Cells 3(9): 613-23. 
Portella, G., S. A. Cumming, et al. (1998). "Transforming growth factor beta is essential 
for spindle cell conversion of mouse skin carcinoma in vivo: implications for tumor 
invasion." Cell Growth Differ 9(5): 393-404. 
Prahlad, V., M. Yoon, et al. ( 1  998). "Rapid movements of vimentin on microtubule 
tracks: kinesin-dependent assembly of intermediate filament networks." J Cell Biol 
143(1): 159-70. 
Turkson, J., T. Bowman, et al. (1998). "Stat3 activation by Src induces specific gene 
regulation and is required for cell transformation." Mol Cell Biol 18(5): 2545-52. 
Vindevoghel, L., A. Kon, et al. (1998). "Smad-dependent transcriptional activation of 
human type VII collslgen gene (COL7A1) promoter by transforming growth factor-beta." 
J Biol Chem 273(21): 13053-7. 
Waseem, A., Y. Alam, et al. (1998). "Isolation, sequence and expression of the gene 
encoding human keratin 13." Gene 2 15(2): 269-79. 
Yoon, M., R. D. Moir, et al. (1998). "Motile properties of vimentin intermediate filament 
networks in living cells." J Cell Biol 143(1): 147-57. 
Zhang, Y., X. H. Feng, et al. (1998). "Smad3 and Smad4 cooperate with c-Junlc-Fos to 
mediate TGF-beta-induced transcription. " Nature 394(6696): 909- 13. 
Agochiya, M., V. G. Brunton, et al. (1999). "Increased dosage and amplification of the 
focal adhesion kinase gene in human cancer cells." Oncogene 18(41): 5646-53. 
Boyer, A. S., C. P. Erickson, et al. (1999). "Epithelial-mesenchymal transformation in the 
embryonic heart is mediated through distinct pertussis toxin-sensitive and TGFbeta signal 
transduction mechanisms." Dev Dyn 214(1): 81-91. 
Bromberg, J. F., M. H. Wrzeszczynska, et al. (1999). "Stat3 as an oncogene." Cell 98(3): 
295-303. 
Eisma, R. J., J. D. Spiro, et al. (1999). "Role of angiogenic factors: coexpression of 
interleukin-8 and vascular endothelial growth factor in patients with head and neck 
squamous carcinoma." Laryngoscope 109(5): 687-93. 
Hasegawa, T., H. Xiao, et al. (1999). "Cloning of a GADD34-like gene that interacts with 
the zinc-finger transcription factor which binds to the p21(WAF) promoter." Biochem 
Biophys Res Commun 256(1): 249-54. 
Ikebe, T., M. Shinohara, et al. (1999). "Gelatinolytic activity of matrix metalloproteinase 
in tumor tissues correlates with the invasiveness of oral cancer." Clin Exp Metastasis 
17(4): 315-23. 
Izmailova, E. S., E. Wieczorek, et al. (1999). "A GC-box is required for expression of the 
human vimentin gene." Gene 235(1-2): 69-75. 
Izmailova, E. S. and Z. E. Zehner (1999). "An antisilencer element is involved in the 
transcriptional regulation of the human vimentin gene." Gene 230(1): 11 1-20. 
Vimentin is an intermediate filament protein normally expressed in cells of 
Landis, S. H., T. Murray, et al. (1999). "Cancer statistics, 1999." CA Cancer J Clin 49(1): 
8-31, 1. 
Liberati, N. T.. M. B. Datto, et al. (1999). "Smads b i d  directly to the Jun family of AP-1 
transcription factors." Proc Natl Acad Sci U S A 96(9): 4844-9. 
Parkin, D. M., P. Pisani, et al. (1999). "Estimates of the worldwide incidence of 25 major 
cancers in 1990." Int J Cancer 80(6): 827-41. 
Piek, E., A. Moustakas, et al. (1999). "TGF-(beta) type I receptor1ALK-5 and Smad 
proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast 
epithelial cells." J Cell Sci 112 ( Pt 24): 4557-68. 
Waseem, A., B. Dogan, et al. (1999). "Keratin 15 expression in stratified epithelia: 
downregulation in activated keratinocytes." J Invest Dermatol 112(3): 362-9. 
Wong, C., E. M. Rougier-Chapman, et al. (1999). "Smad3-Smad4 and AP-1 complexes 
synergize in transcriptional activation of the cJun promoter by transforming growth 
factor beta." Mol Cell Biol 19(3): 1821-30. 
Xia, W., Y. K. Lau, et al. (1999). "Combination of EGFR, HER-2/neu, and HER-3 is a 
stronger predictor for the outcome of oral squamous cell carcinoma than any individual 
family members." Clin Cancer Res 5(12): 4164-74. 
Ye, S., C. Whatling, et al. (1999). "Human stromelysin gene promoter activity is 
modulated by transcription factor ZBP-89." FEBS Lett 450(3): 268-72. 
Bowman, T., R. Garcia, et al. (2000). "STATs in oncogenesis." Oncogene 19(21): 2474- 
88. 
Boyer, B., A. M. Valles, et al. (2000). "Induction and regulation of epithelial- 
mesenchymal transitions." Biochem Pharmacol 60(8): 1091-9. 
Choy, L., J. Skillington, et al. (2000). "Roles of autocrine TGF-beta receptor and Smad 
signaling in adipocyte differentiation." J Cell Biol 149(3): 667-82. 
Helrnke, B. P., R. D. Goldman, et al. (2000). "Rapid displacement of vimentin 
intermediate filaments in living endothelial cells exposed to flow." Circ Res 86(7): 745- 
52. 
Hong, B. K., H. M. Kwon, et al. (2000). "Coexpression of cyclooxygenase-2 and matrix 
metalloproteinases in human aortic atherosclerotic lesions." Yonsei Med J 41 (1): 82-8. 
Horvath, C. M. (2000). "STAT proteins and transcriptional responses to extracellular 
signals." Trends Biochem Sci 25(10): 496-502. 
Itoh. S., F. Itoh, ~t al. (2000). "Signaling of transforming growth factor-beta fami!y 
members through Smad proteins." Eur J Biochem 267(24): 6954-67. 
Izmailova, E. S ., S. R. Snyder, et al. (2000). "A Stat 1 alpha factor regulates the expression 
of the human vimentin gene by IFN-gamma." J Interferon Cytokine Res 20(1): 13-20. 
Massague, J., S. W. Blain, et al. (2000). "TGFbeta signaling in growth control, cancer, 
and heritable disorders." Cell 103(2): 295-309. 
Massague, J. and D. Wotton (2000). "Transcriptional control by the TGF-betdSmad 
signaling system." Embo J 19(8): 1745-54. 
Massague, J. and Y. G. Chen (2000). "Controlling TGF-beta signaling." Genes Dev 
14(6): 627-44. 
Mitchell, S. H., P. E. Murtha, et al. (2000). "An androgen response element mediates 
LNCaP cell dependent androgen induction of the hK2 gene." Mol Cell Endocrinol 168(1- 
2): 89-99. 
Verrecchia, F., M. Pessah, et al. (2000). "Tumor necrosis factor-alpha inhibits 
transforming growth factor-beta ISmad signaling in human dermal fibroblasts via AP- I 
activation." J Biol Chem 275(39): 30226-31. 
Wieczorek, E., Z. Lin, et al. (2000). "The zinc finger repressor, ZBP-89, binds to the 
silencer element of the human vimentin gene and complexes with the transcriptional 
activator, Spl." J Biol Chem 275(17): 12879-88. 
Akhurst, R. J. and R. Derynck (2001). "TGF-beta signaling in cancer--a double-edged 
sword." Trends Cell Biol 1 l(11): S44-5 1. 
Bancroft, C. C., Z. Chen, et al. (2001). "Coexpression of proangiogenic factors IL-8 and 
VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK- 
MAPK and IKK-NF-kappaB signal pathways." Clin Cancer Res 7(2): 435-42. 
Bhowmick, N. A., M. Ghiassi, et al. (2001). "Transforming growth factor-beta1 mediates 
epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism." 
Mol Biol Cell 12(1): 27-36. 
Bhowmick, N. A., R. Zent, et al. (2001). "Integrin beta 1 signaling is necessary for 
transforming growth factor-beta activation of p38MAPK and epithelial plasticity." J Biol 
Chem 276(50): 46707- 13. 
Bromberg, J. F. (2001). "Activation of STAT proteins and growth control." Bioessays 
23(2): 161-9. 
Derynck, R., R. J. Akhurst, et al. (2001). "TGF-beta signaling in tumor suppression and 
cancer progression." Nat Genet 29(2): 117-29. 
Ellenrieder, V., S. F. Hendler, et al. (2001). "TGF-beta-induced invasiveness of 
pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase 
plasminogen activator system." Int J Cancer 93(2): 204-1 1. 
Ellenrieder, V., S. F. Hendler, et al. (2001). "Transforming growth factor beta1 treatment 
leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells 
requiring extracellular signal-regulated kinase 2 activation." Cancer Res 61(10): 4222-8. 
Garcia, R., T. L. Bowman, et al. (2001). "Constitutive activation of Stat3 by the Src and 
JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells." 
Oncogene 20(20): 2499-5 13. 
Hagedorn, H. G., B. E. Bachmeier, et al. (2001). "Synthesis and degradation of basement 
membranes and extracellular matrix and their regulation by TGF-beta in invasive 
carcinomas (Review)." Int J Oncol 18(4): 669-81. 
Hasina, R. and M. W. Lingen (2001). "Angiogenesis in oral cancer." J Dent Educ 65(11): 
1282-90. 
Keates, A. C., S. Keates, et al. (2001). "ZBP-89, Spl, and nuclear factor-kappa B regulate 
epithelial neutrophil-activating peptide-78 gene expression in Caco-2 human colonic 
epithelial cells." J Biol Chem 276(47): 437 13-22. 
Miyazono, K., K. Kusanagi, et al. (2001). "Divergence and convergence of TGF- 
beta/BMP signaling." J Cell Physiol 187(3): 265-76. 
Miyazono, K. (2001). "[Recent advances in the research on TGF-betalsmad signaling 
pathways]." Tanpakushitsu Kakusan Koso 46(2): 105- 10. 
Moustakas, A., S. Souchelnytskyi, et al. (2001). "Smad regulation in TGF-beta signal 
transduction." J Cell Sci 114(Pt 24): 4359-69. 
Peron, P., M. Rahmani, et al. (2001). "Potentiation of Smad transactivation by Jun 
proteins during a combined treatment with epidermal growth factor and transforming 
growth factor-beta in rat hepatocytes. role of phosphatidylinositol3-kinase-induced AP-1 
activation." J Biol Chem 276(13): 10524-3 1. 
Rich, J., A. norton, et al. (2001). "Transforming growth factor-beta signaling in cancer." 
Microsc Res Tech 52(4): 363-73. 
Savagner, P. (2001). "Leaving the neighborhood: molecular mechanisms involved during 
epithelial-mesenchymal transition:" Bioessays 23(10): 912-23. 
Verrecchia, F., M. L. Chu, et al. (2001). "Identification of novel TGF-beta /Smad gene 
targets in dermal fibroblasts using a combined cDNA microarray/promoter 
transactivation approach." J Biol Chem 276(20): 17058-62. 
Verrecchia, F., C. Tacheau, et al. (2001). "Induction of the AP-1 members c-Jun and 
JunB by TGF-beta/Smad suppresses early Smad-driven gene activation." Oncogene 
20(18): 2205- 1 1. 
Verrecchia, F., L. Vindevoghel, et al. (2001). "Smad3/AP-1 interactions control 
transcriptional responses to TGF-beta in a promoter-specific manner." Oncogene 20(26): 
3332-40. 
Verrecchia, F., J. Rossert, et al. (2001). "Blocking spl transcription factor broadly 
inhibits extracellular matrix gene expression in vitro and in vivo: implications for the 
treatment of tissue fibrosis." J Invest Dermatol 116(5): 755-63. 
Yamada, A., S. Takaki, et al. (2001). "Identification and characterization of a 
transcriptional regulator for the lck proximal promoter." J Biol Chem 276(21): 18082-9. 
Zajchowski, D. A., M. F. Bartholdi, et al. (2001). "Identification of gene expression 
profiles that predict the aggressive behavior of breast cancer cells." Cancer Res 61(13): 
5 168-78. 
Zavadil, J., M. Bitzer, et al. (2001). "Genetic programs of epithelial cell plasticity 
directed by transforming growth factor-beta." Proc Natl Acad Sci U S A 98(12): 6686-91. 
Zheng, X. L., S. Matsubara, et al. (2001). "Epidermal growth factor induction of 
apolipoprotein A-I is mediated by the Ras-MAP kinase cascade and Spl." J Biol Chem 
276(17): 13822-9. 
Ang, K. K., B. A. Berkey, et al. (2002). "Impact of epidermal growth factor receptor 
expression on survival and pattern of relapse in patients with advanced head and neck 
carcinoma." Cancer Res 62(24): 7350-6. 
Bakin, A. V., C. Rinehart, et al. (2002). "p38 mitogen-activated protein kinase is required 
for TGFbeta-mediated fibroblastic transdifferentiation and cell migration." J Cell Sci 
115(Pt 15): 3193-206. 
Deb, D., M. Scian. et al. (2002). "Hetero-oligomerization does not compromise 'gain of 
function' of tumor-derived p53 mutants." Oncogene 21(2): 176-89. 
Crande, M., A. Franzen, et al. (2002). "Transforming growth factor-beta and epidermal 
growth factor synergistically stimulate epithelial to mesenchymal transition (EMT) 
through a MEK-dependent mechanism in primary cultured pig thyrocytes." J Cell Sci 
115(Pt 22): 4227-36. 
Helfand, B. T., A. Mikami, et al. (2002). "A requirement for cytoplasmic dynein and 
dynactin in intermediate filament network assembly and organization." J Cell Biol 
157(5): 795-806. 
Kawata, R., T. Shimada, et al. (2002). "Enhanced production of matrix 
metalloproteinase-2 in human head and neck carcinomas is correlated with lymph node 
metastasis." Acta Otolaryngol 122(1): 101-6. 
Levy, D. E. and J. E. Darnell, Jr. (2002). "Stats: transcriptional control and biological 
impact." Nat Rev Mol Cell Biol 3(9): 651-62. 
Mitchell, C. R., M. Folkard, et al. (2002). "Effects of exposure to low-dose-rate (6O)co 
gamma rays on human tumor cells in vitro." Radiat Res 158(3): 31 1-8. 
Perrais, M., P. Pigny, et al. (2002). "Induction of MUC2 and MUCSAC mucins by factors 
of the epidermal growth factor (EGF) family is mediated by EGF 
receptor/Ras/Raf/extracellular signal-regulated kinase cascade and Spl." J Biol Chem 
277(35): 32258-67. 
Schneider, G. B., Z. Kurago, et al. (2002). "Elevated focal adhesion kinase expression 
facilitates oral tumor cell invasion." Cancer 95(12): 2508- 15. 
Thiery, J. P. (2002). "Epithelial-mesenchymal transitions in tumour progression." Nat 
Rev Cancer 2(6): 442-54. 
Wakefield, L. M. and A. B. Roberts (2002). "TGF-beta signaling: positive and negative 
effects on tumorigenesis." Curr Opin Genet Dev 12(1): 22-9. 
Wang, N. and D. Stamenovic (2002). "Mechanics of vimentin intermediate filaments." J 
Muscle Res Cell Motil 23(5-6): 535-40. 
Aronsohn, M. S., H. M. Brown, et al. (2003). "Expression of focal adhesion kinase and 
phosphorylated focal adhesion kinase in squamous cell carcinoma of the larynx." 
Laryngoscope 1 13(11): 1944-8. 
Derynck, R. and Y. E. Zhang (2003). "Smad-dependent and Smad-independent pathways 
in TGF-beta family signalling." Nature 425(6958): 577-84. 
Fridman, R., M. Toth, et al. (2003). "Cell surface association of matrix metalloproteinase- 
9 (gelatinase B)." Cancer Metastasis Rev 22(2-3): 153-66. 
Gilles, C., M. Polette, et al. (2003). "Transactivation of vimentin by beta-catenin in 
human breast cancer cells." Cancer Res 63(10): 2658-64. 
Grunert, S., M. Jechlinger, et al. (2003). "Diverse cellular and molecular mechanisms 
contribute to epithelial plasticity and metastasis." Nat Rev Mol Cell Biol4(8): 657-65. 
Lu, Z., S. Ghosh, et al. (2003). "Downregulation of caveolin-1 function by EGF leads to 
the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced 
tumor cell invasion." Cancer Cell 4(6): 499-51 5. 
McLean, G. W., E. Avizienyte, et al. (2003). "Focal adhesion kinase as a potential target 
in oncology." Expert Opin Pharmacother 4(2): 227-34. 
Nicolas, F. J. and C. S. Hill (2003). "Attenuation of the TGF-beta-Smad signaling 
pathway in pancreatic tumor cells confers resistance to TGF-beta-induced growth arrest." 
Oncogene 22(24): 3698-7 1 1. 
Singh, S., S. Sadacharan, et al. (2003). "Overexpression of vimentin: role in the invasive 
phenotype in an androgen-independent model of prostate cancer." Cancer Res 63(9): 
2306- 1 1. 
Thomas, S. M., F. M. Coppelli, et al. (2003). "Epidermal growth factor receptor- 
stimulated activation of phospholipase Cgamma-1 promotes invasion of head and neck 
squamous cell carcinoma." Cancer Res 63(17): 5629-35. 
Tian, F., S. DaCosta Byfield, et al. (2003). "Reduction in Smad213 signaling enhances 
tumorigenesis but suppresses metastasis of breast cancer cell lines." Cancer Res 63(23): 
8284-92. 
Wells, A. and J. R. Grandis (2003). "Phospholipase C-gamma1 in tumor progression." 
Clin Exp Metastasis 20(4): 285-90. 
Wu, Y., X. Zhang, et al. (2003). "c-Jun and the dominant-negative mutant, TAM67, 
induce vimentin gene expression by interacting with the activator Spl." Oncogene 
22(55): 889 1-901. 
Zhang, X., I. H. Diab, et al. (2003). "ZBP-89 represses vimentin gene transcription by 
interacting with the transcriptional activator, Spl." Nucleic Acids Res 3 l(11): 2900-14. 
Do, N. Y., S. C. Lim, et al. (2004). "Expression of c-erbB receptors, MMPs and VEGF in 
squamous cell carcinoma of the head and neck." Oncol Rep 12(2): 229-37. 
Glick, A. B. (2004). "TGFbetal, back to the future: revisiting its role as a transforming 
growth factor." Cancer Biol Ther 3(3): 276-83. 
Grandis, J. R. and J. C. Sok (2004). "Signaling through the epidermal growth factor 
receptor during the development of malignancy." Pharmacol Ther 102(1): 37-46. 
Herrmann, H. and U. Aebi (2004). "Intermediate filaments: molecular structure, assembly 
mechanism, and integration into functionally distinct intracellular Scaffolds." Annu Rev 
Biochem 73: 749-89. 
Huber, M. A., N. Azoitei, et al. (2004). "NF-kappaB is essential for epithelial- 
mesenchymal transition and metastasis in a model of breast cancer progression." J Clin 
Invest 1 14(4): 569-81. 
Kim, M. M. and J. A. Califano (2004). "Molecular pathology of head-and-neck cancer." 
Int J Cancer 112(4): 545-53. 
Nakajima, S., R. Doi, et al. (2004). "N-cadherin expression and epithelial-mesenchymal 
transition in pancreatic carcinoma." Clin Cancer Res lO(12 Pt 1): 4125-33. 
Recher, C., L. Ysebaert, et al. (2004). "Expression of focal adhesion kinase in acute 
myeloid leukemia is associated with enhanced blast migration, increased cellularity, and 
poor prognosis." Cancer Res 64(9): 3 191-7. 
Schlaepfer, D. D., S. K. Mitra, et al. (2004). "Control of motile and invasive cell 
phenotypes by focal adhesion kinase." Biochim Biophys Acta 1692(2-3): 77-102. 
Shintani, S., T. Ishikawa, et al. (2004). "Growth-regulated oncogene-1 expression is 
associated with angiogenesis and lymph node metastasis in human oral cancer." 
Oncology 66(4): 3 16-22. 
Shintani, S., C. Li, et al. (2004). "Expression of vascular endothelial growth factor A, B, 
C, and D in oral squamous cell carcinoma." Oral Oncol40(1): 13-20. 
Wu, Y., I. Diab, et al. (2004). "Stat3 enhances vimentin gene expression by binding to the 
antisilencer element and interacting with the repressor protein, ZBP-89:" Oncogene 
23(1): 168-78. 
Bachman, K. E. and B. H. Park (2005). "Duel nature of TGF-beta signaling: tumor 
suppressor vs. tumor promoter." Curr Opin Oncol 17(1): 49-54. 
Bernier, J. and J. S. Cooper (2005). "Chemoradiation after surgery for high-risk head and 
neck cancer patients: how strong is the evidence?" Oncologist ?0(3): 215-24. 
Davies, M., M. Robinson, et al. (2005). "Induction of an epithelial to mesenchymal 
transition in human immortal and malignant keratinocytes by TGF-beta1 involves 
MAPK, Smad and AP-1 signalling pathways." J Cell Biochem 95(5): 918-31. 
Howell, G. M. and J. R. Grandis (2005). "Molecular mediators of metastasis in head and 
neck squamous cell carcinoma." Head Neck 27(8): 710-7. 
Korsching, E., J. Packeisen, et al. (2005). "The origin of vimentin expression in invasive 
breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or 
histogenesis from progenitor cells with bilinear differentiation potential?" J Path01 
206(4): 45 1-7. 
McLean, G. W., N. 0 .  Carragher, et al. (2005). "The role of focal-adhesion kinase in 
cancer - a new therapeutic opportunity." Nat Rev Cancer 5(7): 505-15. 
Miyazaki, H., V. Patel, et al. (2005). "Growth factor-sensitive molecular targets identified 
in primary and metastatic head and neck squamous cell carcinoma using microarray 
analysis." Oral Oncol. 
Willipinski-Stapelfeldt, B., S. Riethdorf, et al. (2005). "Changes in cytoskeletal protein 
composition indicative of an epithelial-mesenchymal transition in human micrometastatic 
and primary breast carcinoma cells." Clin Cancer Res 1 l(22): 8006-14. 
Yeudall, W. A,, H. Miyazaki, et al. (2005). "Uncoupling of epidermal growth factor- 
dependent proliferation and invasion in a model of squamous carcinoma progression." 
Oral Oncology 41 : 698-708. 
